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ABSTRACT 
 
Medicinal plants have provided important advances in the treatment of numerous 
diseases and many plant-derived drugs are currently in use or under investigation for the 
treatment of many ailments including cancer. 
A phytochemical analysis of the methanol extract from the seed of Saponaria 
vaccaria L. cultivated in Saskatchewan was performed which resulted in the detection 
of several bisdesmosidic saponins. A high-performance liquid chromatographic method 
using photodiode array and single quadrupole electrospray mass detection for analysis 
and profiling was developed. Due to their structural similarities, purification of 
bisdesmosidic saponins was challenging. However, monodesmosidic saponin 
Vaccaroside B and cyclopeptides Segetalin A, Segetalin B, and a new cyclopeptide, 
segetalin I [whose structure was proposed to be cyclo(Gly1-Pro2-Tyr3-Tyr4-Pro5-Phe6)], 
were purified employing various chromatographic techniques such as HPLC, VLC, 
PTLC).  
 Crude methanol extracts of S. vaccaria seed were evaluated for cytotoxic activity 
using the methyl-thiazol-tetrazolium non-radioactive cell proliferation assay (MTT 
assay). Various concentrations of the extract (2-50 μg/mL) were tested against a series 
of four human cancer cell lines (WiDr, colon; MDA-MB-231, breast; NCI-417, lung and 
PC-3, prostate). The human foreskin (BJ)-derived normal human fibroblast cell line 
CRL-2522 was included as a non-cancerous control. Results showed that cytotoxic 
activities from the seed extract were greater than commercially available Quillaja 
saponaria saponin.  
 vi
The human cancer cell lines were also exposed to fractions containing high titers 
of saponins as well as semi-purified saponins (ca. 80%). All bisdesmosidic saponins and 
fractions thereof showed cytotoxicity against the cell lines studied. The effect was 
particularly strong in breast and prostate cancer cell lines with IC50 values in the range 
1–4 μg/mL. Monodesmosidic saponins, phenolics and cyclopeptides did not show 
activity even at the highest concentration (50 μg/mL) tested in this study. Chemical 
modifications of the saponin structures resulted in an overall decrease in activity, but an 
increase in selectivity in comparison to CRL-2522. Time and concentration-dependent 
studies using the nuclear stains propidium iodide and Hoechst 33342, demonstrated that 
the stimulation of apoptosis was the mechanism of cytotoxic action. When breast and 
prostate cell lines were exposed to small amounts (4-7 μM) of bisdesmosidic saponins 
Segetalin H (MW 1448) and Segetalin I (MW 1464), it was observed that apoptosis was 
induced at an early incubation time (4-10 h). Activation of caspases and changes in 
membrane potential were determined by flow cytometry. 
As a result of this study, we propose that triterpene bisdesmosidic saponins from 
the seed of Saponaria vaccaria L. represent a new type of drug having potential 
antitumor/anticancer activity due to their ability to induce apoptosis in vitro in human 
cancer cell lines at low concentrations. These compounds are extracted from a plant that 
can be easily cultivated using conventional agricultural equipment in Western Canada. 
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GLOSSARY 
 
Adjuvants: Pharmacological or immunological agents that modify the effect of other 
agents (e.g., drugs, vaccines) while having few if any direct effects when given by 
themselves. In this sense, they are roughly analogous to chemical catalysts. 
 
Anticancer: Used against or tending to arrest or prevent cancer. Anticancer activity can 
only be determined from human trials. 
 
Antimicrobial: Destroying or inhibiting the growth of microorganisms.  
 
Antineoplastic: Inhibiting or preventing the growth and spread of neoplasms or 
malignant cells. 
 
Antitumor: Effective against a model tumor system in vivo. Implies selectivity against 
tumor compared to host non-cancerous cells. 
 
Apaf-1: Apoptotic protease activating factor 1 is a cytosolic protein involved in cell 
death or apoptosis. When Cytochrome c is released from the mitochondria, it interacts 
with Apaf-1 and dATP to form the apoptosome, a large oligomeric protein complex 
which can activate caspase 9. 
 
Bcl-2:  The prototype for a family of mammalian genes and the proteins they produce. 
They govern mitochondrial outer membrane permeabilization (MOMP) and can be 
either pro-apoptotic (Bax, BAD, Bak and Bok among others) or anti-apoptotic 
(including Bcl-2 proper, Bcl-xL, and Bcl-w, among an assortment of others).  
 
Cancer: A general name for more than 200 distinct diseases in which abnormal cells 
grow out of control; a malignant tumor. 
 
 xxxii
Cancer cells: The smallest indivisible components which in aggregate constitute a 
malignant tumor. 
 
Carcinoma: Cancer that begins in the lining or covering of an organ. Skin, lung, 
breasts, prostate are epithelial lining cell cancers and constitute the most common forms 
of cancer in the human body. 
 
Caspases: Cysteine-dependent ASPartyl-specific proteASE. A family of proteins that 
are one of the main executors of the apoptotic process and inflammation. They belong to 
a group of enzymes known as cysteine proteases and exist within the cell as inactive 
pro-forms or zymogens. These zymogens can be cleaved to form active enzymes 
following the induction of apoptosis. As proteases, they are enzymes that cleave other 
proteins. They are called cysteine proteases, because they use a cysteine residue to cut 
those proteins, and are called caspases because the cysteine residue cleaves their 
substrate proteins at the aspartic acid residue. 
 
Chemoprevention: Ingestion of non-toxic quantities of chemical agents (dietary or 
pharmaceutical) that are capable of preventing, inhibiting or reversing the process of 
carcinogenesis. 
 
Chemotherapy: The use of drugs to treat cancer. 
 
Chemotherapy Drugs: Cell killing and growth inhibitory agents utilized alone or in 
combination for the treatment of cancer. 
 
Cultivar: A cultivated plant that has been selected and given a unique name because it 
has desirable characteristics (decorative or useful) that distinguish it from otherwise 
similar plants of the same species. When propagated it retains those characteristics. 
 
Cytotoxic: Toxic to cells in culture. Does not imply any selective effect on cancer cells 
versus normal cells. Subtypes are: 
 xxxiii
Cytostatic: stopping cell growth (often reversible) 
Cytocidal: killing cells. 
 
Fas ligand or FasL: A type II transmembrane protein that belongs to the tumor necrosis 
factor (TNF) family. The binding of Fas ligand with its receptor induces apoptosis. Fas 
ligand-receptor interactions play an important role in the regulation of the immune 
system and the progression of cancer. 
 
Glycoside: Any of a group of organic compounds, occurring abundantly in plants, that 
yield a sugar and one or more non-sugar substances on hydrolysis. 
Hormesis (from Greek hormæin, meaning “to excite”) is the term for generally-
favorable biological responses to low exposures to toxins and other stressors. A 
pollutant or toxin showing hormesis thus has the opposite effect in small doses than in 
large doses. In toxicology, hormesis is a dose response phenomenon characterized by a 
low dose stimulation, high dose inhibition, resulting in either a J-shaped or an inverted 
U-shaped dose response. 
Interferons (IFNs): Natural proteins produced by the cells of the immune system of 
most vertebrates in response to challenges by foreign agents such as viruses, parasites 
and tumor cells. Interferons belong to the large class of glycoproteins known as 
cytokines. Interferons are produced by a wide variety of cells in response to the presence 
of double-stranded RNA, a key indicator of viral infection. Interferons assist the 
immune response by inhibiting viral replication within host cells, activating natural 
killer cells, increasing antigen presentation to lymphocytes, and inducing the resistance 
of host cells to viral infection. 
 
Interleukins: A group of cytokines (secreted signaling molecules) that were first seen to 
be expressed by white blood cells (leukocytes, hence the -leukin) as a means of 
communication (inter-). It has been found that interleukins are produced by a wide 
variety of bodily cells. The function of the immune system depends in a large part on 
interleukins, and rare deficiencies of a number of them have been described, all 
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featuring autoimmune diseases or immune deficiency. For example, IL-2 from TH1-
cells, stimulates growth and differentiation of T cell response.  
 
Jurkat cells: An immortalized line of T lymphocyte cells that are used to study acute T 
cell leukemia and T cell signaling. The Jurkat cell line (originally called JM) was 
established in the late 1970s from the peripheral blood of a 14 year old boy with T cell 
leukemia. 
 
Malignant: Used to describe a cancerous tumor. 
 
MTT assay: A laboratory test and a standard colorimetric assay (an assay which 
measures changes in color) for measuring cellular proliferation (cell growth). It can also 
be used to determine cytotoxicity of potential medicinal agents and other toxic 
materials. Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
a tetrazole) is reduced to purple formazan in the mitochondria of living cells. 
 
Neoplasm: A new growth of tissue serving no physiological function: tumor. 
 
Sapogenin:  The non-sugar portion of saponin that is typically obtained by hydrolysis. 
 
Saponin: Any of various plant glycosides that form soapy lathers when mixed and 
agitated with water. They are used in detergents, foaming agents and emulsifiers. While 
some saponins may be very toxic, even lethal, there are other saponins that are being 
researched for its anti-oxidant properties, and used against cancer. 
 
Surfactant: "Surface acting agent". Surfactants are usually organic compounds that are 
amphipathic, meaning they contain both hydrophobic groups (their "tails") and 
hydrophilic groups (their "heads"). Therefore, they are soluble in both organic solvents 
and water. 
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Terpene: Any of a class of hydrocarbons occurring widely in plants and animals and 
empirically regarded as built up from isoprene, a hydrocarbon consisting of five carbon 
atoms attached to eight hydrogen atoms (C5H8). The term is often extended to the 
terpenoids, sometimes referred to as isoprenoids, which are oxygenated derivatives of 
these hydrocarbons. 
 
Traditional Chinese Medicine: Medical science governing the theory and practice of 
traditional Chinese medicine. It includes Chinese medication, pharmacology/herbalogy, 
acupuncture, massage and Qigong. 
 
Tumor: An abnormal benign or malignant mass of tissue that is not inflammatory, 
arises from a variety of causes from cells of preexistent tissue, and possesses no 
physiologic function. 
 
Tumor necrosis factors: The TNF-family refers to a group of cytokines family that can 
cause apoptosis. TNF-alpha is the most well-known member of this class, and 
sometimes referred to when the term "tumor necrosis factor" is used. TNF acts via the 
TNF Receptor (TNF-R) and is part of the extrinsic pathway for triggering apoptosis. 
 
Trypsinization: Releasing cells from the monolayer from one culture vessel to another 
using purified trypsin so that the cells can be easily handled by pipetting and diluting. 
(Trypsin is a popular detachment factor because it digests the proteins that keep the cell 
attached to a surface. Prolonged exposure to trypsin can result in too much of the cell 
being digested, which can cause cell damage or destruction.) 
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CHAPTER 1 
INTRODUCTION 
 
1.1.    Saponins 
Saponins are naturally occurring glycosylated compounds generated by the 
terpenoid biosynthetic pathway, which are found mainly, but not exclusively in the plant 
kingdom (Oleszek, 2002). The occurrence of saponins in plants is widespread but 
concentrations are highly variable. Chemically, the term saponin defines a group of 
structurally diverse molecules which can be divided into three major classes, depending 
on the structure of the aglycone or non-saccharide portion (called the genin or 
sapogenin): triterpene glycosides, steroid glycosides, and steroid alkaloid glycosides 
(Fig. 1.1) (Hostettmann and Marston, 1995). The sugars can be attached as one, two, and 
less commonly three sugar chains and the terms monodesmoside, bidesmoside, and 
tridesmoside has been given to these saponins, respectively (Greek desmos = chain) 
(Joshi et al., 2002, Oleszek, 2002).  
 Steroidal saponins are found in the monocotyledonous plant families (those 
related to the grasses) such as Dioscoreaceae, Liliaceae, Agavaceae and Amaryllidaceae, 
and, among the dicotyledons (the great bulk of plant families), in such as the foxglove 
(Digitalis spp.), nightshade families and in fenugreek (Trigonella foenum-graecum). The 
triterpenoid saponins are rare in the monocotyledons, but are widely present in 
dicotyledons (Leguminosae, Araliaceae, Caryophyllaceae).  Saponins are found in 
various parts of the plant: leaves, stems, roots, bulbs, blossom, and fruit. They are
1 
characterized by their bitter taste, and their ability to hemolyze red blood cells. A single 
plant species may contain a complex mixture of saponins (Sparg et al., 2004). 
 Triterpenoid saponins are found in many cultivated crops and legumes such as 
soybeans, beans, peas, lucerne, and also in onion, tea, spinach, sugar beet, quinoa, 
liquorice, sunflower, horse chestnut, ginseng. Steroidal saponins are common in plants 
used as herbs or for their health-promoting properties including oats, capsicum peppers, 
aubergine, tomato seed, alliums, asparagus, yam, fenugreek, yucca and ginseng 
(Fenwick et al., 1991). Steroidal glycoalkaloids are natural toxins in the Solanaceae 
family. These compounds are also found in common food crops such as in potato and 
tomato, where they are bound to sugar moieties to form glycosides (Morrissey and 
Osbourn, 1999; Arneson and Durbin, 1968).  It is noteworthy that the levels of these 
compounds in commercially available, quality potato tubers and tomatoes do not 
represent a health hazard to humans (Smith et al., 1996). The chemical structures of the 
steroidal glycoalkaloids α-solanine (1) and α -tomatine (2) are shown in Fig. 1.2. 
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Figure 1.1. Skeletal types of sapogenins found in the three principal classes of saponins. 
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Figure 1.2. α-Solanine (1) is one of the glycoalkaloids found in several species of the 
nightshade family (e.g. potatoes and tomatoes). Tomato plants contain the steroidal 
glycoalkaloid, α-tomatine (2), which is a monodesmosidic saponin with a 
tetrasaccharide group. 
 
Two very well known plants containing saponins are oats and tomatoes. Oats 
have both triterpenoid (avenacins) and steroidal (avenacosides) saponins. The avenacin 
family consists of 4 closely related saponins; avenacins A-1 (3) and B-1 are esterified 
with N-methyl anthranilic acid and hence are autofluorescent under UV light. Avenacins 
A-2 and B-2 are esterified with benzoic acid and are only weakly autofluorescent. The 
steroidal oat leaf saponins avenacosides A and avenacoside B (4) both have two sugar 
3 
chains, one at C-3 and one at C-26 (Osbourn et al., 2003; Crombie and Crombie, 1986; 
Begley et al., 1986). The chemical structures of avenacin A-1 and avenacoside B are 
show in Fig. 1.3. 
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Figure 1.3. Structures of the two groups of oat saponins. The monodesmosidic 
triterpenoid avenacin A-1 (3) is the major saponin in oat roots. Bidesmosidic steroid 
avenacoside A (not shown) differs from avenacoside B (4) only in that it lacks the 
terminal β(1Æ3) linked D-glucose molecule. 
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Saponins often occur as complex mixtures, and saponin content and composition 
may vary markedly depending on the genetic background of the plant material, the 
tissue type, the age and physiological state of the plant and environmental factors 
(Hostettmann and Marston, 1995; Rao and Sung, 1995; Hostettmann et al., 1991; 
Fenwick et al., 1991; Price et al., 1987; Roddick, 1974). 
Plants containing a high titer of saponins display a soapy/foamy solution when 
crushed and shaken with water. This characteristic distinguishes them from other plants, 
and because of their natural detergent characteristics, the water extracts of foliage or 
roots of some high saponin containing plants (e.g. Saponaria officinalis L.) were 
historically used as soaps (Osbourn 1996).  Their presence in plants is thought to act as a 
deterrent to herbivores - the taste is generally bitter and astringent and can cause gastric 
irritation if ingested. In contrast, saponins from liquorice are sweet in taste. The toxic 
action of some saponins to fungi is associated with their ability to complex with 
membrane steroids and cause pore-formation (Morrissey and Osbourn, 1999). In 
general, saponins are also highly toxic to some creatures such as fish where the gills are 
permeabilized with concomitant bleeding. If injected into the bloodstream they can 
disrupt the membranes of red cells. (Marston et al., 2000) 
Humans generally do not suffer severe poisoning from saponins since it takes a 
large oral dose of saponins to produce a toxic effect. Because of this, saponins have 
been used in sneezing powders, emetics, and cough syrups to facilitate expectoration. 
Most saponins are also diuretics. Commercially, they are used in toothpaste and in 
gargles, shampoos or foaming agents in drinks such as root beer (Susumu et al., 1993; 
Yoshiaki and Mitsuru, 1992).  They are also used in fire extinguishers as a foam 
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producer and in photographic emulsions. Industrially, they are used in mining for ore 
separation and also in electroplating to minimize acid vapours (Glüçlü-Üstlündağ and 
Mazza, 2007; Cheng et al., 2004; San Martin and Briones, 1999). Although saponins are 
considered a single class of compounds, their structural differences are quite large. This 
is reflected in the great variety of saponins reported from varied sources showing 
diverse biological applications, toxicities and commercial applications (Glüçlü-
Üstlündağ and Mazza, 2007). The biological applications of saponins are described 
below. 
 
1.2. Saponins from Quijalla saponaria M. 
Quillaja saponins are natural tensoactives (or surfactants) derived from the bark 
of Quillaja saponaria M. (family Rosaceae), which is a large evergreen tree indigenous 
to Chile, Peru and Bolivia. They have been used for over 100 years as foaming agents in 
food and beverages, production of photographic films, adjuvants in animal vaccines, 
cosmetics, etc. There are over 300 scientific papers and international patents describing 
the use of quillaja saponins for different applications. Saponins of the quillaja type (Fig. 
1.4) are a complex mixture of glycosylated triterpenes based on quillaic acid, and the 
price of crude extract varies remarkably, depending on grade and purity of extract. Not 
unexpectedly, the population of wild trees in recent years has been decreasing 
dramatically due to continuous harvesting. This has been reflected by an increase in 
extract price over the past few years (San Martin and Briones, 2000; San Martin and 
Briones, 1999). 
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As mentioned above, saponins are considered to be toxic to fish and snails (Price 
et al., 1987). However, quillaja saponins have weak molluscicidal and fish killing 
activities and since these saponins have been shown to have no adverse effects on mice 
and rats, they are categorized as GRAS (generally recognized as safe) for human 
consumption by the FDA of the United States of America (Sen et al., 1998a). 
Quillaja-type saponins are also produced by a number of other plants, 
particularly members of the Caryophyllaceae, several of which not only grow readily in 
the Canadian prairies, and are adaptable to large scale cultivation (Goering et al., 1966). 
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Figure 1.4. The basic structure and substitution positions of the majority of the reported 
saponins from Quillaja saponaria. 
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1.3.    The Caryophyllaceae Family  
The Caryophyllaceae (pink family) is a large and widely distributed family, 
comprising over 2000 species in 80 genera found mostly throughout the North 
Temperate Zone, especially in the northern Mediterranean countries although it is also 
well represented in North America. Most species are herbs or sub-shrubs. Very many 
species and cultivars of Dianthus L., the carnations, pinks, and sweet williams, are 
available from seed merchants, nurserymen, and florists. Gypsophila L. (baby’s breath) 
species and cultivars are also popular for floral arrangements and bouquets, and are 
commonly grown as decorative garden plants (Caryophyllaceae 2008; Rabeler and 
Hartman, 2005; Watson and Dallwitz, 1992; Montana Plant Life). Several members of 
the pink family are known for their saponin content. The genus Saponaria L. was named 
for its soap-like properties.  
 
1.3.1.  Saponaria officinalis L. and Saponaria vaccaria L. 
Saponaria officinalis L. also know as soapwort, bouncing bet, sweet betty, wild 
sweet william, bruisewort, dog cloves, old maids’ pink, soap root, latherwort, fuller’s 
herb, fuller’s grass, foam dock, gill-run-by-the-street saponary, lady-by-the-gate, crow 
soap, hedge pink, farewell summer; was introduced from Europe and has rapidly 
adapted to North America. It is a perennial, often growing 1.5 to 2 meters in height 
(approx. 5 to 6 feet). This species is most often encountered in sandy soil along stream 
banks, roadsides and waste places (Natural Resources Canada, Global Biodiversity 
Information Facility; Ministry of Agriculture, Food and Rural Affairs, Ontario; 
USDA/ARS/GRIN; Montana Plant Life). The medicinal properties of S. officinalis are 
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due to its hormone-like saponins. This plant has a traditional reputation for both the 
internal and external treatment of skin conditions such as eczema, psoriasis, acne and 
boils. Its use as a remedy for gout and rheumatism is probably due to the anti-
inflammatory action of the saponins. Their strongly irritant action in the gut stimulates 
the cough reflex and increases the production of more fluid mucus within the respiratory 
tract. It has been used in the treatment of dry cough. A popular home remedy for poison 
ivy can be derived from the crushed roots of this plant. The root is also said to 
encourage bile flow, and is reported to have an effect on gallstones. It is laxative in quite 
small doses. If ingested for several days, toxic signs are noted in some animals, which 
can include: mild depression, vomiting (in those species that can vomit), abdominal 
pain, diarrhea (which may become bloody). Overall, this toxicosis is not encountered 
frequently (Montana Plant Life; Plants for a future: Saponaria officinalis Database). 
 A similar species, cow cockle (S. vaccaria L. syns. S. hispanica Mill., Vaccaria 
hispanica (Mill.) Rauschert, V. pyramidata Medik., V. segetalis Asch.), also known as 
China cockle and cow-herb, is more slender and only grows to about 1 meter (3 feet) in 
height (Fig. 1.5a). Cow cockle is also an introduced species and is considered a Class 3 
noxious weed in Saskatchewan (The Noxious Weeds Designation Regulations, 1999) 
and in the rest of Canada as a secondary noxious weed (Canada Seeds Act 1986 and 
2005: Weed Classes), although it is grown commercially in California as a cut flower 
(Koike et al., 1999).  This plant grows in areas of fine textured soils, but it is also 
commonly found in cultivated fields, waste places and roadsides. The leaves are 
opposite, 2-8 cm long, smooth, sessile, and blue to green in colour. The flowers, smaller 
than those of  S. officinalis, have 5 petals united to form a calyx, funnel-shaped, pale red 
9 
to deep pink, and loosely grouped at the ends of stems (Fig. 1.5b). It is a prolific 
producer of seeds. These are rough, black, nearly round, 2.5 mm in diameter, and 
enclosed in a capsule. Besides saponins (2-4%), the seed contains protein (12-15%); oil 
(3-4%) and starch (65-70%) (Mazza et al., 1992; Plants for a future: Vaccaria hispanica 
Database).  
 
 
 
a b 
 
 
 
 
 
 
Figure 1.5. Saponaria vaccaria L. (cow cockle). 
 
 
1.3.2. Traditional and medicinal uses of Saponaria vaccaria L. 
 The seeds have been used in Traditional Chinese Medicine (Wang Bu Liu Xing) 
for pain relief, for promoting menstrual discharge and milk secretion, healing wounds, 
as diuretics, astringents, and anticancer agents (Washington, 1974; Smith F. P., 1969; 
Duke and Ayensu, 1985). These properties have been associated with the saponin 
content. The seed also contains cyclopeptides which possess antibiotic and estrogenic 
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properties, and the starch found in the seed is potentially valuable in cosmetics and 
specialty foods. The flowers, leaves, roots and shoots also have similar biological 
properties (Duke and Ayensu, 1985). The sap of the plant is said to be a febrifuge and 
tonic (Chopra et al., 1956). It is used in the treatment of long-continued fevers of a low 
grade type.  The plant is used externally to cure itch (Chopra et al., 1956), and a 
decoction is used to treat skin problems, breast tumors, menstrual problems, deficiency 
of lactation and sluggish labour (Duke and Ayensu, 1985). It has been used in Chinese 
herbal medicine (Chinese name ‘Wang-Bu-Liu-Xing’) to activate blood flow, promote 
milk secretion and in the treatment of amenorrhea and breast infections. All plant parts, 
especially the seed, contain saponins (Fig. 1.6). 
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Figure 1.6. Basic structure of the triterpene saponins found in Saponaria vaccaria L. 
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1.4. Bioactive metabolites of Saponaria vaccaria L. 
 In addition to saponins, other bioactive metabolites isolated from the seed of S. 
vaccaria include alkaloids, cyclopeptides, phenolics, and steroids (Sang et al., 2003). 
Although the processing and properties of cow cockle seed starch have been 
investigated, research on the bioactive constituents of cow cockle seed has largely been 
limited to isolation and identification of individual components.  
 
1.4.1. Saponins 
 Saponins occurring in S. vaccaria seeds are glycosides of triterpenes. The main 
types of saponins correspond to the quillaic acid type and this accounts for 
approximately 65% of total saponins (Fig. 1.7). Also present are gypsogenin 
bisdesmosides (~15%) (Fig. 1.8), gypsogenic acid monodesmosides (~10%) (Fig. 1.9), 
and vaccaric acid bisdesmosides (~10%). Structures of cow cockle saponins are 
presented in Table 1.1.  
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Figure 1.7. Structures of the main quillaic acid bisdesmosides vaccaroside E (5) and 
segetoside I (6). 
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Figure 1.8. Structures of the main gypsogenin type bisdesmosides vaccaroside G (7) 
and segetoside H (8). 
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Vaccaroside A (MW 1134.5457) 
R = H (C54H86O25) (9) 
 
Vaccaroside B (MW 1278.5879) 
R = *Ester (C60H94O29) (10) 
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Figure 1.9.  Structure of the main gypsogenic acid monodesmosides Vaccaroside A and 
Vaccaroside B. 
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Table 1.1. Saponins isolated from cow cockle seed. 
 
 
Saponins Formula Aglycone Ref. 
Segetosides 
Segetoside B C69H106O33 Gypsogenin Sang et al., 2002 
Segetoside C C56H88O26 Gypsogenic acid Sang et al., 1999 
Segetoside D C69H106O34 Quillaic acid Sang et al., 1998 
Segetoside E C72H112O34 Quillaic acid Sang et al., 1998 
Segetoside F C67H104O32 Gypsogenin Sang et al., 2000b 
Segetoside G C70H110O32 Gypsogenin Sang et al., 2000a 
Segetoside H C68H104O33 Gypsogenin Sang et al., 2000a 
Segetoside I C68H104O34 Quillaic acid Sang et al., 2000a 
Segetoside K C54H86O26 Olean-12-ene-23α, 28β-dioic acid 3β, 16α-dihydroxy Sang et al., 2000c 
Segetoside L C60H98O28 Oleanolic acid Xia et al., 2004 
    
Vaccarosides 
Vaccaroside A C54H86O25 Gypsogenic acid Koike et al., 1998 
Vaccaroside B C60H94O29 Gypsogenic acid Koike et al., 1998 
Vaccaroside C C54H86O25 Gypsogenic acid Koike et al., 1998 
Vaccaroside D C54H86O25 3,4-Seco derivative of gypsogenic acid Koike et al., 1998 
Vaccaroside E C66H102O33 Quillaic acid Jia et al., 1998 
Vaccaroside F C65H102O33 Segetalic acid Jia et al., 1998 
Vaccaroside G C66H102O32 Gypsogenin Jia et al., 1998 
Vaccaroside H C65H102O32 Vaccaric acid Jia et al., 1998 
Vaccaroid A C54H86O25 Gypsogenic acid Morita et al., 1997 
Vaccaroid B C60H94O29 Gypsogenic acid Yun et al., 1997 
 
Note: Table originally published in Glüçlü-Üstlündağ et al., 2007. 
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1.4.2. Cyclopeptides 
 The seed also contains cyclopeptides which have been reported to possess 
antibiotic and estrogenic properties. Cyclopeptides represent a group of naturally 
occurring molecules found in several species of plants and microorganisms. The cyclic 
nature of these peptides generally affords a greater stability in comparison with 
corresponding linear peptides. Additional medical and therapeutic applications include 
anticancer, anti-inflammatory, antithrombosis, antidiuretic and hypotensive activity. 
Eight cyclopeptides have been isolated from the seeds of S. vaccaria (Table 1.2). The 
structures of segetalin A (9) and segetalin B (10) are also shown in Fig. 1.10. 
 
 
Table 1.2.  Cyclopeptides identified in cow cockle.* 
 
Compound, 
MW (obs.) C H N O 1 2 3 4 5 6 7 8 9 
Segetalin A 
609.3271 31 43 7 6 gly val pro val trp ala    
Segetalin B 
484.2433 24 32 6 5 gly val ala trp ala     
Segetalin C 
769.3989 40 51 9 7 gly leu his phe ala phe pro   
Segetalin D 
719.3654 37 49 7 8 gly leu ser phe ala phe pro   
Segetalin E 
812.4229 43 56 8 8 gly tyr val pro leu trp pro   
Segetalin F 
954.4442 44 62 10 14 ala ser tyr ser ser lys pro phe ser
Segetalin G 
518.2850 25 38 6 6 gly val lys tyr ala     
Segetalin H 
610.2861 29 38 8 7 gly tyr arg phe ser     
 
*There is a large variability in the type and amount of cyclopeptides found in different 
cow cockle accessions. 
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 Segetalin A (cyclohexapeptide), segetalin B (cyclopentapeptide), segetalin C and 
E (cycloheptapeptides) were first discovered by Itokawa et al. (1995), who reported 
seven cyclopeptides (segetalins A-E, G-H) from this species (Sang et al., 2003). Among 
these, segetalins A, B, G and H showed estrogen-like activity assayed by the increment 
of uterus in ovariectomized rats (Yun et al., 1997; Morita et al., 1995). Segetalin F, the 
largest cyclopeptide found in the seeds of S. vaccaria, was first reported by Morita et al. 
in 2006. They also reported the vasodilatory effect stimulated by segetalins A, D, F, G 
and H against norepinephrine-induced contractions of rat aorta. 
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Figure 1.10.  Segetalin A (11) and segetalin B (12), a cyclohexapeptide and a 
cyclopentapeptide isolated from the seeds of Saponaria vaccaria L. Glycine is 
numbered as the first amino acid. 
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1.4.3. Phenolic acids  
 Phenolic acids found in the seeds of S. vaccaria include the phenylpropanoid 
glycoside (13) and the free phenolic acid dihydroferulic acid (14) (Fig. 1.11). These are 
hydroxylated derivatives of cinnamic acid. The importance of these compounds relates 
to their potent antioxidative properties and their potential use as protective factors 
against cancer and heart diseases (Sang et al, 2003). 
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Figure 1.11. Phenolic acids from Saponaria vaccaria L. 
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1.4.4. Flavonoids  
 Flavonoids are polyphenolic compounds possessing 15 carbon atoms; two 
benzene rings joined by a linear three carbon chain. Flavonoids have shown many 
biological and pharmacological activities, such as antioxidant activity, tumor-growth-
inhibitory activity in various cancer cell lines in vitro, and reducing activity against the 
risk of breast cancers (Sang et al., 2003). Vaccarin (15), a flavone isolated from cow 
cockle seeds is shown below (Sang et al., 2000d). 
 
 
 
 O
O
OGlu
HO
O
OH
OH
OAra
HO
OH
 
 
 
 
 
 
 
Vaccarin (15) 
 
 
1.5. Health benefits of saponins 
There have been several reviews in recent years of published reports about 
various biological properties of saponins (e.g. Glüçlü-Üstlündağ and Mazza, 2007; 
Corea et al., 2005; Francis et al., 2002, Barr et al., 1998; Sen et al., 1998b; Yoshiki et 
al., 1998; Kensil, 1996; Hostettman and Marston, 1995.).  
Saponins function as a ”natural antibiotic” for plants and now researchers are 
testing them for antifungal activity and how saponins may help humans fight infections, 
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combat microbes and viruses and boost the effectiveness of certain vaccines.  The 
natural tendency to ward off microbes may prove to be especially useful for treating 
difficult-to-control fungal and yeast infections (Glüçlü-Üstlündağ and Mazza, 2007; 
Francis et al., 2002; Ferreira and Llodrá, 2000).    
Saponins are being researched extensively for cholesterol control. It is 
hypothesized that the saponins either bind with bile salts or cause the bile salts to bind to 
the polysaccharides in dietary fiber. Either way the bile salts are unavailable to bind with 
cholesterol, thus altering cholesterol metabolism (Oakenfull and Topping, 1983 – cited 
in Joshi et al., 2002). The blood cholesterol-lowering properties of dietary saponins are 
of particular interest in human nutrition. 
Among the most widely known saponins with biological activities are the cardiac 
glycosides from Digitalis lanata Ehrh. and D.  purpurea L. (Scrophulariaceae) which 
include digoxin (16) and digitoxin (17), and the cytotoxic saponin glycyrrhizin (18) from 
Glycyhrrhiza glabra L. (Leguminosae). Digoxin, the most commonly used preparation 
of digitalis, is a steroid saponin found in D. lanata Ehrh. (foxglove plant) that is used in 
modern medicine to increase the force of the systolic contractions and prolong duration 
of the diastolic phase in congestive heart failure. It is also used to help normalize some 
dysrhythmias (abnormal types of heartbeat). Digitalis drugs lower venous pressure in 
hypersensitive heart ailments, elevate blood pressure in a weak heart, act as a diuretic, 
and reduce edema. An exhaustive review published by Rahimtoola and Tak (1996) cited 
a large number of references and has detailed data and descriptions of a large number of 
studies and all early trials (Rahimtoola 2004). Digitalis was first prescribed by English 
physician and botanist William Withering (1741-1799), who used it in the treatment of 
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edema. In “An account of the foxglove, and some of its medicinal uses” he summarized 
the results of his extensive studies of the drug and described the symptoms of digitalis 
toxicity (Digitalis 2008). 
Glycyrrhizin (18) is extracted from liquorice root. It is used to sweeten and 
flavor many foods and pharmaceutical preparations. There is a long history of its use to 
treat illnesses such as peptic ulcer (inhibits the enzymes 15-hydroxy-prostaglandin 
dehydrogenase and delta-13-prostaglandin reductase); colds and other viral infections 
(may stimulate interferon production; reported expectorant/cough suppressant 
properties); microbial and parasitic infections (may stimulate the immune system); 
cancers (again, possibly related to immune system function) (Licorice 2008; Davis and 
Morris, 1991; Fenwick et al., 1990). 
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A large number of saponins isolated from both animal and marine species and 
certain derivatives thereof, have also been tested in vitro and in vivo for their toxicity 
against a number of cells and their effectiveness against some tumors. Many laboratories 
from around the world have focused their interest on the inhibitory and apoptosis-
inducing effects of saponins. 
 
1.6. Cancer and Saponins 
 Advances in the treatment and prevention of cancer require the continuous 
development of novel and improved chemotherapeutic and chemopreventive agents. 
Many saponins have been shown in bioassays to be cytotoxic (in vitro), anti-tumoral (in 
vivo) and chemopreventive (in vitro and in vivo) and many of their therapeutic 
properties and mechanisms of action have been attributed to the diverse sapogenins and 
the complexity of the sugar chains. 
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1.6.1.  Saponins as a preventive strategy 
Studies at the Department of Nutritional Science of the University of Toronto 
have indicated that dietary sources of saponins offer preferential chemopreventive 
strategy in lowering the risk of human cancers.  At present, damage to normal cells 
limits cancer therapy. One of the most exciting prospects for saponins is how they 
appear to inhibit or kill cancer cells since they may be able to do it without killing 
normal cells in the process. It was found that at the cellular level, saponins inhibit the 
growth and viability of cancer cells. In animal studies, mice which were fed with 
saponin-enriched diets and then exposed to colon cancer carcinogens, showed a lower 
incidence of cancerous and precancerous tumours than the controls. As saponins bind 
cholesterol, it is believed that they have a natural affinity for binding to cancer cell 
membranes as these cells have an altered membrane structure with higher amounts of 
cholesterol-like compounds (Rao and Gurfinkel, 2000; Rao 1997; Rao and Sung, 1995). 
Specific examples of saponins isolated from diverse sources that have been reported to 
have important time-dependent anticancer properties include Lee et al., 2006; Kang et 
al., 2005, Oh and Lee, 2004; Yanamandra et al., 2003; Oh and Sung, 2001. 
 
1.6.2. Saponins as a therapeutic strategy 
 Numerous reports and review papers on the biological actions and effects of 
saponins in animal systems have been published in the past few years (Sparg et al., 
2004; Francis et al., 2002). Saponins isolated from different plants and animals have 
been shown to specifically inhibit the growth of cancer cells in vitro and in vivo. 
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Depending to the nature of saponins and the cell line studied, cytotoxicities measured as 
IC50 values range from 4 ng/mL to 20 μg/mL (Lacaille-Dubois 2000).  
 Avicins, a family of triterpenoid saponins isolated from the Australian desert tree 
Acacia victoriae (Leguminosae) selectively inhibited growth of tumour cell lines by cell 
cycle arrest in human breast cancer cell line and apoptosis in a leukaemia cell line 
(Mujoo et al., 2001) and reduced both tumour incidence and multiplicity in a murine 
skin carcinogenesis model (Hanusek et al., 2001) suggesting that avicins could also 
suppress the development of human skin cancer and other epithelial malignancies. 
Haridas et al. (2001) also demonstrated that purified avicins, Avicin D and Avicin G, 
induced apoptosis in the Jurkat human T cell line by affecting mitochondrial function. 
Several studies on ginsenoside Rg3, a triterpenoid glycoside from Panax ginseng 
(Araliaceae), showed multiple antiproliferative activity of this saponin towards human 
prostate carcinoma cells including cell cycle arrest at G1 phase and stimulation of 
apoptosis (Yue et al., 2007). De Tomassi et al. (2000) also reported the isolation of 
antiproliferative triterpene bidesmosidic saponins from the Indian plant Trevesia 
palmate (Araliaceae) against a panel of three cell lines, where the sugar chain esterified 
at C-28 was crucial for the antiproliferative activity. Structure-activity studies on the 
accumulation of cisplatin and cytotoxicity in human colon cancer cells by triterpene 
saponins jenisseensosides A, B, C, and D from Silene jenisseensis (Caryophyllaceae) 
suggested the importance of the acyl moiety for activity (Gaidi et al., 2002). 
 Two novel triterpene bisdesmosides, designated as enterolosaponin A and B, 
were isolated from Enterolobium contotisiliquum (Leguminosae) and also evaluated for 
their macrophage-oriented cytotoxic activity. The former exhibited a highly selective 
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cytotoxicity against BAC1.2F5 mouse macrophages, but the macrophage death caused 
by this saponin was shown to be neither necrotic nor due to induction of apoptosis from 
morphology of the dead cells, whose cytosol occurred in vacuolation (Mimaki et al., 
2003).  
 Tubeimoside I and tubeimoside V isolated from tubers of Bolbostemma 
paniculatum (Cucurbitaceae), often used in traditional Chinese medicine for the 
treatment of tumours as well as for detoxification, showed potent anti-tumorigenic effect 
in carcinogenesis of mouse skin (Yu et al., 2006) and induction of apoptosis in human 
glioblastoma cells (Cheng et al., 2006), respectively. 
 Dioscin, a steroidal saponin isolated from the roots of the Chinese herb 
Polygonatum zanlanscianense (Liliaceae), exerted significant inhibitory effects on the 
growth of the human leukaemia cell HL-60, inducing differentiation and apoptosis 
(Wang et al., 2001).  Triterpene bisdesmosides saponins securioside A and B from 
Securidaca innapendiculata (Polygalaceae), a plant used in traditional Chinese medicine 
because of its many bioactivities, showed specific toxic activity against macrophage 
colony-stimulating factor-induced growth of macrophages. Interestingly, the 
securiosides seemed to have no or considerably weaker effects against other cells 
including thymocytes, bone marrow cells and tumour cell lines or even macrophages 
stimulated by growth factors other than macrophage colony-stimulating factor, revealing 
a high degree of structure-related specificity. They are believed to be the primary 
compounds of new drugs for the treatment of pathological states in which macrophage 
proliferation occurs (Kuroda et al., 2001; Yui et al., 2001).  
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 Dr. Campbell at the University of California, San Francisco screened crude 
aqueous herbal extracts of seventy-one Chinese medicinal herbs against a panel of five 
human breast cancer cell lines. Seven of these extracts -including Saponaria vaccaria- 
demonstrated at least 50% growth inhibition on all five cell lines (Campbell et al., 
2002). Twelve of the most active extracts were further evaluated against a panel of 
human and murine cancer cell lines (breast, lung, pancreas and prostate) and the extract 
of S. vaccaria showed very high growth inhibitory activity against all cell lines tested 
(Shoemaker et al., 2005).  
 The use of traditional Chinese medicinal herbs as antineoplastic agents as well as 
the isolation of the active antitumor compounds and the study of their mechanisms of 
action is an essential tool in the discovery of new leads for the treatment of cancer. 
There is enough scientific evidence showing that the cytotoxicity and antitumor activity 
of saponins is by induction of apoptosis. 
 
1.7. Apoptosis. An introduction. 
 Apoptosis, or programmed cell death, is a normal component of the development 
and health of multicellular organisms. Cells die in response to a variety of stimuli and 
during apoptosis they do so in a controlled, regulated fashion. This makes apoptosis 
distinct from another form of cell death called necrosis in which uncontrolled cell death 
leads to lysis of cells, inflammatory responses and, potentially, to serious health 
problems (Wyllie, 1997) (Fig. 1.12). Apoptosis, by contrast, is a process in which cells 
play an active role in their own death (which is why apoptosis is often referred to as cell 
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suicide). In the end apoptosis reduces cells to small apoptotic bodies that are swiftly 
cleared up by phagocytosis (Platt et al., 1999).  
 
 
Necrosis Apoptosis 
Inflammation Phagocytosis by 
macrophages or 
nearby cells 
(no inflammation) 
Cells swell 
Organelles damaged 
Chromatin altered 
Cells lyse 
Organelles destroyed 
Chromatin destroyed 
Cell contents 
released 
Cells shrink 
Organelles undamaged 
Chromatin marginated 
Formation of apoptotic bodies 
Organelles intact 
Chromatin fragmented 
Cell contents 
retained 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12. Two cell death pathways, necrosis and apoptosis. Necrosis involves 
breakdown of the cellular membrane, which leads to leakage of intracellular proteins to 
the extracellular space and subsequently, inflammation. Necrosis usually affects large 
groups of cells while apoptosis typically involves single cells that undergo organised 
destruction of the cellular cytoskeleton and formation of apoptotic bodies, which are 
phagocytosed without an inflammatory reaction.  
(Adapted from: http://escuela.med.puc.cl/pub/PatologiaGeneral/Figuras/fig2.26.gif) 
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 Apoptosis is a normal cellular process and is essential for the proper 
development and maintenance of the organism. Apoptosis is also necessary for the 
destruction of cells considered a threat such as cells infected with viruses, cells with 
DNA damage, cancerous cells, and cells of the immune system after they have fulfilled 
their function. (Dales et al., 2001; Wyllie, 1997; Zimmermann and Green 2001). 
 Apoptosis, in general, confers advantages during an organism’s life cycle. For 
example, the differentiation of fingers and toes in a developing human embryo occurs 
because cells between the fingers apoptose; the result is that the digits separate. Between 
50 and 70 billion cells die each day due to apoptosis in the average human adult. 
Unregulated apoptosis could exacerbate or cause diseases such as: 
 • AIDS, in which T helper cell numbers plummet. Part of the dramatic decline in 
 these cells might be caused by healthy T helper cells being tricked into 
 committing suicide; 
 • neurodegenerative diseases like Alzheimers; 
 • ischemic stroke, when restricted blood flow to certain regions of the brain can 
 lead to neural death through increased apoptosis; 
 • cancer, in which tumor cells lose their ability to undergo apoptosis; 
 • autoimmune disease, in which self-reactive immune cells trick normal body 
 cells to kill themselves; 
 • viral disease 
 (Jakubowski 2008). 
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 Apoptosis has been a target of intensive research in recent years. This is reflected 
by over 140,000 publications to date with the great majority of them published during 
the last decade (PubMed search, January 2008).  
Apoptosis involves a biochemical cascade including such proteins as Bcl-2, Bax, 
Apaf-1 or apoptotic protease activating factor-1, caspases such as caspase-9, caspase-3, 
and caspase-7, as well as proteins involved in digestion of proteins, degradation of 
DNA, and phagocytosis (Fig. 1.13).  
 
*DISC = Death Inducing Signalling Complex
•IAP = Inhibitors of Apoptosis Proteins 
Apoptosis 
Nucleus
Apoptosis can be 
induced in 
response to 
various signals 
from inside and 
outside the cell 
“ligation” 
Oncogenes
* 
Type 1 
Type 2
caspase-8 and 9 (initiatior)
 
caspases-3, -6, and -7 (effector) 
 
Bcl-2, Bcl-XL (pro-survival) 
 
Bax, Bad, Bid (pro-apoptotic) 
 
Smac = Second Mitochondria-derived Activator of Caspases  
 
 
Figure 1.13. Schematic representation of some major apoptotic signalling pathways.  
(Adapted from: http://www.celldeath.de/encyclo/aporev/revfigs/revfig_6.htm) 
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1.7.1. Causes of apoptosis 
 A wide variety of stimuli are capable of inducing apoptosis. Some are universal 
and can produce apoptosis in almost any cell, while most apoptosis-inducing factors 
show some selection of their targets (Rich et al., 2000). The decision of a cell to 
undergo apoptosis depends upon the balance between positive signals keeping the cell 
alive (e.g., growth factors and interleukins such as IL-2) and negative signals that call 
for cellular suicide (e.g., oxidative stress, DNA damage, improper protein folding, and 
specific molecules such as tumor necrosis factor alpha and beta (TNF-α and TNF-β), 
and the FAS ligand (FasL) that binds to the Fas receptor, or CD95 (Schulze-Osthoff et 
al., 1998).   
 Apoptosis does not require new transcription or translation, suggesting that the 
molecular machinery required for cell death lay dormant in the cell, and just requires 
appropriate activation. These signals can be internal, external or an apoptosis-inducing 
factor (Wajant, 2002; Schulze-Osthoff et al., 1998).   
 
Internal signals. 
Internal damage to a cell such as that produced by oxidative damage, causes Bcl-2 to 
activate Bax which creates holes in the mitochondrial membrane. These holes allow the 
entry of cytochrome c into the cytoplasm. Cytochrome c binds to APAf-1 forming 
complexes that aggregate to form apoptosomes. This aggregation requires energy from 
ATP. The apoptosomes activate caspase-9. Caspase-9 cleaves and activates caspase-3 
and caspase-7. These executioner caspases activate a cascade of proteolytic activity that 
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leads to the digestion of structural proteins, DNA degradation, and ultimately 
phagocytosis (Zhang et al., 2004/2005). 
 
External signals. 
FasL and TNF-α/β can bind to the cell membrane receptors Fas and TNF, respectively. 
Binding of the Fas or TNF ligands results in the activation of caspase-8 which unleashes 
a proteolytic cascade similar to that activated by caspase-9. This cascade results in 
phagocytosis of the cell. An example of this process is when cytotoxic T cells bind to a 
target cell. The T cells produce more FasL that binds to the Fas receptor on the target 
cell leading to apoptosis of the target cell (Wajant, 2002). 
 
Apoptosis-inducing factor (AIF). 
This apoptosis pathway is more common in neurons and is a caspase-independent 
process. AIF is normally present in the intermembrane space of mitochondria. When 
AIF is released from the mitochondria, it migrates to the cell nucleus, binds to DNA, 
and triggers DNA degradation and ultimately cell death (Baehrecke, 2002). 
 
1.7.2. Apoptosis and cancer 
 Research to date has shown that apoptosis is a phylogenetically conserved form 
of cell death that is intricately and precisely regulated inside the cell by gene products. 
Malfunctions of any aspect of this death machinery may directly result in various 
diseases. Cancer, for example, may be viewed as a result of ineffective apoptosis and 
hence a net gain of cells due to unrestrained proliferation. On the other hand, cancer 
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cells themselves may evade immune surveillance by triggering apoptosis of patrolling 
immune cells (Zhang et al., 2004/2005). 
Some viruses associated with cancers use tricks to prevent apoptosis of the cells 
they have transformed. Several human papilloma viruses (HPV) have been implicated in 
causing cervical cancer. One of them produces a protein (E6) that binds and inactivates 
the apoptosis promoter p53 (Tungteakkhun and Duerksen-Hughes, 2008). Epstein-Barr 
Virus (EBV), the cause of mononucleosis and associated with some lymphomas 
produces a protein similar to Bcl-2 and another protein that causes the cell to increase its 
own production of Bcl-2. Both these actions make the cell more resistant to apoptosis 
(thus enabling a cancer cell to continue to proliferate) (Cuconati and White, 2002; 
Henderson et al., 1993). 
Even cancer cells produced without the participation of viruses may have tricks 
to avoid apoptosis. Some B-cell leukemias and lymphomas express high levels of Bcl-2, 
thus blocking apoptotic signals they may receive. The high levels result from a 
translocation of the Bcl-2 gene into an enhancer region for antibody production (Israels 
and Israels, 1999). Melanoma (the most dangerous type of skin cancer) cells avoid 
apoptosis by inhibiting the expression of the gene encoding Apaf-1 (Soengas et al., 
2001). Some cancer cells, especially lung and colon cancer cells, secrete elevated levels 
of a soluble "decoy" molecule that binds to FasL, plugging it up so it cannot bind Fas. 
Thus, cytotoxic T cells (CTL) cannot kill the cancer cells by the mechanism shown 
above (Pitti et al., 1998). Other cancer cells express high levels of FasL, and can kill any 
cytotoxic T cells (CTL) that try to kill them because CTL also express Fas (but are 
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protected from their own FasL) (Ma et al., 2005, Houston and O’Connell, 2004; 
http://biology-pages.info Sep. 2007).  
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CHAPTER 2 
HYPOTHESIS AND OBJECTIVES 
 
HYPOTHESIS 
 
 Recent studies with saponins from diverse sources indicate that the cytotoxic 
activity shown against many types of malignant cells occurs through stimulation of 
apoptosis. Therefore it is postulated that: 
 
1) Saponins have potential anticancer activity and that this effect occurs in a 
concentration- and time- dependent manner. 
  
2) Saponaria vaccaria saponins induce apoptosis.  
 
3) S. vaccaria can be used as sustained source of saponins for the study and 
development of these compounds as a new class of drug for the treatment of 
cancer. 
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OBJECTIVES 
 
Main objective: To investigate the biological activities of Saponaria vaccaria L. seed 
components particularly for their antitumor effects 
 
1. To grow sufficient amounts of Saponaria vaccaria to provide the material for extracts 
to be tested 
 
2. To prepare extracts from Saponaria vaccaria seed, and to test these extracts for 
cytotoxic activity in a panel consisting of different types of human tumor cells (WiDr, 
colon; MDA-MB-231, breast; NCI-417, lung; PC-3, prostate) and a human non-
malignant cell line (CRL-2522, fibroblast) used as a control 
 
3. To fractionate extracts, evaluate their cytotoxicity and elucidate the chemical 
composition of the extracts 
 
4. To test partially-purified saponins and other components of the seed 
 
5. To evaluate structure activity-relationships by chemical modifications of the saponin 
structures 
 
6. To examine apoptosis as a potential mechanism of action of Saponaria vaccaria 
saponins 
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CHAPTER 3 
EXPERIMENTAL 
 
 
3.1. Plant material and saponin extracts 
 Different varieties of cow cockle seed were obtained for this study. Saponaria 
vaccaria ‘Scott WT’ (wild type) was obtained from Eric Johnson, Agri-Food and 
Agriculture Canada, Scott Experimental Farm, Scott, Saskatchewan. Seed of S. vaccaria 
cv. ‘Pink Beauty’ (PB) and ‘White Beauty’ (WB) were obtained from CN Seeds Ltd, 
Pymoor, UK, and the Mongolia variety (MG) was obtained from the USDA Seed 
Repository.  
 Four to five rows of each seed variety were hand seeded in the University of 
Saskatchewan Crop Science plots (5 ¯ 20 ft) in the summer of 2003 and 2004. Seeds 
were planted 0.50 to 0.75 inch deep at a rate of 3 seeds and spaced 1 ft apart. Plants 
were organically grown (hand-weeded, no pesticides, indigenous N2) with minimum 
irrigation until seedlings were observed. Bulk seed was harvested in the fall. 
 The herbal extract, Wang-Bu-Liu-Xing (WBLX), was purchased from a mail 
order supplier, Botanicum Herbs (botanium.com). Quillaja saponin (QS), having 
sapogenin content of approximately 25%, was purchased from Sigma.  
Seeds (50 mg) were finely ground and extracted with 70% methanol (2 mL). The 
methanol extracts were then concentrated and a pre-determined amount of these extracts 
(estimated saponin content of 2-4% by wt) were added to liquid cultures containing the 
human cancer cell lines WiDr (colon), MDA-MB-231 (breast), and NCI-417 (lung) for
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evaluation of their cytotoxic effects. The concentration of extract tested ranged from 50 
to 3.13 μg/mL. Cancer cell lines were chosen because of their incidence in humans and 
the difficulty of treating these tumors with standard chemotherapy.  
For comparative purposes, a commercially available crude saponin extract from 
Quillaja saponaria M. (Rosaceae), and from Quinoa (Chenopodium quinoa Willd., 
Chenopodiaceae) were also used. 
 
 
3.2. Determination of the cytotoxic activity of plant extracts 
3.2.1. Cell lines and culture 
Four human tumor cell lines were used for screening of cow cockle extracts for 
cytotoxic activity: WiDr (ATCC # CCL 218) human colon cancer, MDA-MB-231 
(ATCC # HTB 26) human breast cancer, NCI-417 (CRL-5809) human lung cancer and 
PC-3 (ATCC # CRL-1435) human prostate cancer. CRL-2522 human BJ foreskin 
(normal fibroblasts) was used as control. 
Cell lines were initiated from stocks which were cryopreserved in liquid-phase 
nitrogen. Stock cultures were maintained in RPMI Medium 1640 with L-glutamine 
supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic solution. 
Cells were grown in 20 mL media in T-75 flasks (Falcon) at 37oC in humidified 5% 
CO2.  
Typically, cells required feeding every 3-4 days and sub-culturing (passaging) once per 
week. Cells were always fed the day prior to harvest for the MTT experimental 
procedure.  
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3.2.2. Sub-culturing (passaging) 
Confluent monolayer cultures of WiDr, MDA-MB 231, PC-3 and CRL-2522 
were passaged as described below. 
 Media was completely removed by aspiration with a Pasteur pipette using 
vacuum suction. A 0.25% trypsin-EDTA solution (1 mL) was added to the culture flask 
and allowed to spread over the entire monolayer. Excess trypsin was removed by 
suction. The flask was placed in an incubator (approx. 30 seconds for MDA-MB-231 
and 1-2 minutes for WiDr, PC-3 and CRL-2522). Once the cells appeared to have 
detached from the flask, trypsin was neutralized by adding 10mL of the medium to the 
flask and pipetting the media repeatedly over the flask bottom surface to ensure all cells 
were detached. The cell suspension was transferred to a sterile 15mL centrifuge tube and 
centrifuged for 7 minutes at 300-400 xg (IEC Centra CL2 Benchtop Centrifuge). The 
supernatant was removed from the cell pellet by suction and the cells were resuspended 
in 10mL of media. A single cell suspension was obtained by pipetting the cells in and 
out to prepare appropriate dilutions of the cell suspension: 
 For WiDr, a 1:50 dilution was generally required: the cell suspension (1mL) is 
transferred to new centrifuge tube, fresh media (4mL) is added, mixed, and 1mL is then 
transferred to a new T-75 flask containing 19mL of fresh media. 
For MDA-MB-231, a 1:40 dilution was used: the cell suspension (1mL) is 
transferred to new centrifuge tube, fresh media (3mL) media is added, mixed, and 1mL 
is then transferred to a new T-75 flask containing 19 mL of fresh media. 
PC-3. 1:100 dilution (as described for WiDr). 
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CRL-2522. A 1:8 dilution was generally used. Cell suspension (2.5mL) was 
transferred to a new T-75 flask containing 17.5mL of fresh media. 
 These splits were found to be optimal to allow the cell cultures to be fed every 3-
4 days following sub-culturing. Feeding was done by removing media by aspiration with 
a Pasteur pipette and adding fresh media (20 mL) to the flask. Cell suspensions were 
sub-cultured once weekly. 
 Since NCI-417 does not form a monolayer in the flask, but free aggregates in 
solution, a different methodology was employed in order to get a confluent suspension 
culture. Sub-culturing was done by transferring media from a T-75 flask containing the 
cells in suspension to two sterile 15mL centrifuge tubes and centrifuging for 7 minutes 
at 300-400 xg. The supernatant was removed from the cell pellet by suction and the cells 
were resuspended in 10mL media. Pellets from the two centrifuge tubes were then 
combined and triturated to obtain a single cell suspension. Vigorous trituration was 
required in order to obtain a single cell suspension. A 1:20 dilution was achieved by 
transferring 1mL of the cell suspension to a new T-75 flask containing 19mL of fresh 
media. This split was found to be required in order for cultures to be fed 3-4 days 
following sub-culturing, and sub-cultured once weekly. As cells grew suspended in the 
culture media, they cells were fed by transferring the cell suspension into two-15mL 
centrifuge tubes and centrifuging for 7 minutes at 300-400 xg. The supernatant was then 
removed from the cell pellet by suction and cells were resuspended in 10mL media. 
Pellets were combined from the two centrifuge tubes and triturated in order to obtain a 
single cell suspension. The cells were now transferred into a new T-75 flask, added 
10mL more media and placed it in the incubator. 
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3.2.3. Harvest of cells for bioassays 
Cultures were always fed the day prior to harvest for the cytotoxic bioassays. In 
preliminary experiments the number of cells required for seeding into each microwell to 
obtain the desired absorbance of about 0.300-0.400 was determined by plating cells at 
different densities. For cell lines WiDr, NCI-417 and CRL-2522, 2,500 cells/well (or 
50μL of a cell suspension of 0.5 × 105 cells/mL) was chosen. For MDA-MB-231, 5,000 
cells/well (or 50μL of a cell suspension of 1.0 × 105 cells/mL) were used. 
 
3.2.3.1. Harvesting WiDr, MDA-MB 231, PC-3 and CRL-2522 
Harvesting of these cell lines are performed according to the protocol described 
below. 
 Media was completely removed from the flask by aspiration with a Pasteur 
pipette using vacuum suction. A 0.25% trypsin-EDTA solution (1mL) was added to the 
culture flask and allowed to spread over the entire monolayer.  Excess trypsin was 
removed by suction. The flask was placed in an incubator (approx. 30 seconds for 
MDA-MB-231 and 1-2 minutes for WiDr, PC-3 and CRL-2522) and once cells appear 
to have detached from the flask, trypsin was neutralized by adding 10mL medium to the 
flask and pipetting the media repeatedly over the flask bottom surface to ensure all cells 
were detached. The cell suspension was then transferred into a sterile 15mL centrifuge 
tube and centrifuged for 7 minutes at 300-400 xg. The supernatant was removed from 
the cell pellet by suction; cells were resuspended in 10mL media and triturated to obtain 
single cell suspension. This was the “stock” cell suspension. 
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 The cell count was done manually using a hemocytometer. Typically, a T-75 
flask of WiDr contained approximately 5 × 107 cells and a “stock” cell suspension 
required 1:20 dilution for the cell count. A T-75 flask of MDA-MB-231 contained 
approximately 2 × 107 cells and a “stock” cell suspension required 1:10 dilution for the 
cell count. A T-75 flask of CRL-2522 contained approximately 5 × 106 cells and a 
“stock” cell suspension required 1:2 dilution for the cell count. Appropriate dilutions 
from the “stock” cell suspension with media was performed to obtain a “working” cell 
suspension of 0.5 × 105 cells/mL for WiDr , PC-3 and CRL-2522 or 1.0 × 105 cells/mL 
suspension for MDA-MB-231. 
 
3.2.3.2. Harvesting NCI-417 
 The harvesting of the NCI-417 cell line was performed as described below. 
 Media from a T-75 flask containing the cells in suspension was transferred to 
two sterile 15mL centrifuge tubes. The tubes were centrifuged for 7 minutes at 300-400 
xg. The supernatant was removed from the cell pellet by suction and the cells were 
resuspended in 10mL media. Pellets from the two centrifuge tubes were combined and 
triturated to obtain a single cell suspension. Vigorous trituration was required in order to 
obtain a single cell suspension. The cell count was done manually using a 
hemocytometer. A T-75 flask of NCI-417 typically contained approximately 5 × 106 
cells and no dilution of “stock” cell suspension was required for the cell count. An 
appropriate dilution of “stock” cell suspension was prepared with the media to obtain a 
“working” cell suspension of 0.5 × 105 cells/mL. 
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3.3. Preparation of drug solutions for cytotoxic assay 
 
- Pimozide (MW = 461.56) 
Pimozide stock was prepared by dissolving pimozide (110.8mg) in absolute ethanol 
(100mL). An aliquot (10μL) of this solution was added to the first row of wells 
containing 90μL media. 
 
- Ethanol control 
Absolute ethanol (10μL) was added to first row of wells containing 90μL media. 
 
- 5-Fluorouracil (MW = 130.08) 
A stock solution “A” was prepared dissolving of 5-fluorouracil (97.56mg) in 0.2N 
NaOH (5mL). Then 160μL of stock “A” were diluted to a total volume of 10.0mL with 
RPMI media. 10μL were added to first row of wells containing 90μL media. 
 
- NaOH (0.2N) control (MW = 40.0) 
NaOH (0.4g) was dissolved in H2O (50mL). An aliquot (10μL) was added to the first 
row of wells containing 90μL media. 
 
- NaOH (0.2N) control 
NaOH (160μL, 0.2N) was diluted up to a total volume of 10.0mL with RPMI media. An 
aliquot (10μL) was added to first row of wells containing 90μL media. 
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- Vinblastine sulfate (MW = 909.1)  
(Testing range 3.75–120μm) 
Vinblastine sulfate (43.6mg) was dissolved in H2O (10mL). An aliquot (5μL) was added 
to first row of wells containing 95μL media. 
 
- Vinblastine sulfate (MW = 909.1)  
(Testing range 0.375–12μm) 
Vinblastine sulfate (4.36mg) was dissolved in H2O (10mL). An aliquot (5μL) was added 
to first row of wells containing 95μL media. 
 
3.4. Preparation of seed extract solutions 
 Seeds were harvested, and cleaned from debris. Seeds (1 g) were finely ground 
and extracted with 25 mL of aqueous methanol (70%) in an IKA® T25 basic Ultra 
Turrax® homogenizer. The methanol (MeOH) extract was centrifuged for 5-10 min at 
300-400 xg and the supernatant was set aside. The pellet was resuspended in 70% 
MeOH containing 0.2% ammonium acetate, centrifuged, and the supernatant was pooled 
with the previous one. The combined extract was evaporated and the residue was 
transferred into a pre-weighed vial. The weight was recorded. 
 The dried crude extract was then dissolved in water (2mL) and sonicated. The 
suspension was loaded into a C18 Sep-Pak cartridge (1 g), and four different fractions 
were eluted as follows: 
Fraction 1: 100% H2O (10 mL) 
Fraction 2: 30% MeOH (10 mL) 
 44
Fraction 3: 70% MeOH (10 mL)  
Fraction 4: 100% MeOH (10 mL) 
 All fractions were evaporated until dryness using a Büchi Rotavapor–R and 
weighed. All fractions were analysed by HPLC-PDA-MS and an aliquot of the saponin-
containing fraction 3 (5mg) was dissolved in DMSO (0.1mL) and RPMI medium 
(4.9mL) without FBS and an antibiotic-antimycotic solution to yield a stock solution of 
1 mg seed extract / mL medium. The stock solution was used for cytotoxic evaluation 
against the above described cancer cells using the cell proliferation “MTT” bioassay.  
 
3.5.  Cell proliferation assay “MTT” (in vitro bioassay) 
3.5.1.  Standard CellTiter 96® assay protocol for 96-well plates 
The anticancer activity of the extracts was evaluated using the CellTiter 96® 
non-radioactive cell proliferation assay (Fig. 3.1). The CellTiter 96® assay is based on 
the cellular conversion of a tetrazolium salt into a formazan product that is easily 
detected using a 96-well plate reader. The assay is performed by the addition of a 
premixed optimized Dye Solution to culture wells of a 96-well plate containing various 
concentrations of test substance to be measured.  During 4-hour incubation, living cells 
reduce the soluble yellow tetrazolium component of the Dye Solution (MTT) to 
insoluble purple formazan crystals (Fig. 3.2).  The Solubilization/Stop Solution is then 
added to the culture wells to solubilize the formazan product and the absorbance at 
570nm is recorded using a 96-well plate reader.  The intensity of the color absorbance is 
directly proportional to the level of cell proliferation or viability (Promega Technical 
Bulletin No. 112, 1999; Pagé, 1997; Sieuwerts et al., 1995). 
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 Prepare 96-well plate with 
plant extract (50µg/mL) 
 
Incubate 37°C, 24-72h, 
5% CO2 
 
 
Add dye solution  
 
Incubate 37°C, 4h, 
5% CO2
 
 
Add solubilization/sto 
 
 
 
 
Figure 3.1.   CellTiter 96® non-radioactive cell proliferation assay flowchart. 
 
Figure 3.2. Molecular structure of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl- 
tetrazolium bromide (MTT) and its corresponding reaction product (formazan). 
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3.6.  Preparation of assay plates for determination of IC50 values 
Each drug or seed extract was analyzed in triplicate in a bioassay and each 
bioassay was performed a minimum of two times. The cytotoxic activities were 
evaluated at concentrations of 50, 25, 12.5, 6.25, 3.125 and 1.5625µg/mL using the cell 
lines. Ninety microlitres (90µL) of the assay medium was added into wells that 
contained the highest concentration of plant extract tested (row A).  Also 100µL of 
medium was added into the blank control (row H, columns 1-6), and 50µL to negative 
control wells (row F, columns 1-6) and the remaining wells. The first concentration of 
50µg/mL was prepared by addition of 10µL of the test extract solution into the first row 
of wells. Using a multichannel pipettor, 50µL two-fold serial dilutions for the extracts 
across the well plate were performed (Fig. 3.3).   
 
3.7.  Color development and data recording 
Dye solution (15µL) was added to each well, and the plate incubated at 37°C for 
4 h in a humidified 5% CO2 atmosphere. After 4h, Solubilization/Stop Solution (100µL) 
was added to each well. The plate was allowed to stand overnight in a sealed container 
with a humidified atmosphere at room temperature to completely solubilize formazan 
crystals prior to data recording. The absorbance at 570nm was recorded using a 96-well 
microplate reader (ThermoLab System Multiskan Spectrum Microplate Spectro-
photometer). 
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  Extract 
1 
Extract 
2 
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3 
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4 
Final Concentration  1 2 3 4 5 6 7 8 9 10 11 12 
50µg/mL A             
25µg/mL B             
12.5µg/mL C             
6.25µg/mL D             
3.13µg/mL E             
1.57µg/mL F             
Negative control G       
Blank control H       
Plate 1 
WiDr 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Two-Fold serial dilution for plant extracts at six different concentrations in a 
96-well plate. 
 
 
3.8.  Data calculation 
3.8.1.  Percentage mortality 
The growth ratio of cancer cells under different concentrations of each plant 
extract was calculated by the following formula: 
Y (%) = (1 − T / C) × 100 
Where:    Y = Growth ratio of cancer cell mortality at each sample concentration  
    T = Mean absorbance of treated cells 
    C = Mean absorbance of negative control 
Discard
50µL 
Take 50μL 
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3.8.2. Calculation of IC50 values 
 Optical density (OD) values were plotted against the logarithmic values of the 
concentrations. The corresponding half value of the negative control (NC) is then 
extrapolated.  Example: if the corrected absorbance value for the NC is 0.156, half of 
this is 0.078 (0.156/2=0.078). This means conversion of MTT to formazan if only half 
of the total number of cells in the NC was alive OR half were dead). The corresponding 
value to this log concentration is then calculated. An example is shown in Fig. 3.4. 
IC50 comparison of saponin-containing fraction CC-19 and cisplatin
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0.8
1
1.2
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e
CC-19 
IC50 = inv log (-0.042) = 
 0.91 μg/mL 
Cisplatin 
IC50 = inv log (1.034) = 
10.81mM = 3.3 μg/mL 
IC50 comparison of saponin-containing fraction CC-19 and cisplatin on human breast 
cancer cell line MDA-MB-231 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. IC50 comparison of saponin-containing fraction CC-19 and cisplatin on 
human breast cancer cell line MDA-MB-231. 
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3.9. Preparation of seed material and chromatographic separations 
3.9.1. Materials 
All solvents used for the extraction of seed and fractionation and purification of 
extracts were purchased from BDH Inc. (Toronto, Ont., Canada) or E. Merck 
(Darmstadt, Germany).  All solvents were of analytical grade and used without further 
purification.  Acetonitrile used for HPLC analysis was HPLC grade.  
 
3.9.2. Fractionation of saponin extracts by reverse phase column chromatography 
 (RPCC) using gradient elution 
The following protocol was designed and performed by Dr. John Balsevich 
(NRC-PBI). Saponaria vaccaria L. seed (200g) was treated with 100 mL water for 3 
days. The seeds were removed from the water and ground up with 90% aqueous 
methanol (MeOH). The solids were removed by centrifugation and the extract defatted 
with hexane (Hex). The Hex extract was discarded and the MeOH extract concentrated 
in vacuo to approximately 100 mL. Concentrate was applied to glass column (2 cm i.d.) 
containing 100 g Supelco Discovery DSC-18Lt reverse phase packing which had been 
equilibrated in water for a few hours. After the column was packed, 50-100 mL fractions 
were collected from a gradient system starting from 0 to 100% MeOH in 5% increments 
of MeOH. 
3.9.3. Fractionation of saponin extracts by column chromatography (CC) using an 
 isocratic elution system 
A larger chromatographic separation by gravity column using a divinylbenzene 
polymer as stationary phase (Amberchrome resin CG-300S) was performed with 15 g of 
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saponin mixture (SPM). SPM was provided by Dr. J. Balsevich (NRC-PBI) from a 
different large scale fractionation of the methanolic extract of cow cockle seeds. A 
mixture of methanol:water:acetic acid [MeOH:H2O:CH3COOH (80:20:0.01)] was used 
as the mobile phase (isocratic). Twenty two fractions (100 mL each) were collected 
from the column (CC-1 to CC-22) and aliquots were analyzed by HPLC-PAD-MS. 
 
3.9.4. Purification of cyclopeptides from the seed of S. vaccaria L. 
Cyclopeptide containing fraction ‘CP A,B,D+’ was obtained from the 70% 
MeOH extract of the seeds of cow cockle as follows: an aqueous concentrate of the dry 
MeOH extract was extracted with ethyl acetate (EtOAc, 2×) and the EtOAc soluble 
fraction separated and evaporated to dryness. The dry residue was then re-suspended in 
diethyl ether (Et2O) to eliminate non-polar impurities, and the Et2O insoluble fraction 
was labelled as ‘CP A,B,D+’. A diagram of the extraction procedure is shown below 
(Fig. 3.5). 
 
3.9.5. Fractionation by vacuum liquid chromatography (VLC) using gradient 
 elution 
Vacuum liquid chromatography of cyclopeptide-enriched fraction (CP A,B,D+) was 
performed according to Pelletier et al. (1986). The adsorbent silica-gel (Type H, size 10-
40μ) purchased from Sigma Chemical Co. (St. Louis, MO., USA) was first loaded into a 
glass funnel and allowed to settle by gentle tapping. The vacuum was then applied, and 
the adsorbent was compressed to a hard layer by pressing with a rubber stopper and 
tapping. 
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S. vaccaria L. PBM seeds (200 g) 
70% MeOH extraction (100 mL) 
(70%) Crude MeOH extract 
Evaporate MeOH (rotary evaporator, 30° C) 
MeOH (discard) Aqueous concentrate (100 mL) 
EtOAc extraction (200 mL, 3¯) 
Aqueous fraction 
(sugars, phenolics, 
polar CPs, saponins,) 
EtOAc soluble fraction 
(non-polar CPs) 
Evaporate EtOAc   (rotary evaporator, 30° C) 
Residue EtOAc (discard) 
Re-suspend with Et2O (50 mL)  
Et2O insoluble fraction 
 (CP A,B,D+) 
Et2O soluble fraction 
 (discard) 
 
Figure 3.5. Separation of cyclopeptide-containing fraction ‘CP A,B,D+’ from the 
methanol extract of the seeds of cow cockle. 
 
 
Once uniform and tight packing of the adsorbent was achieved, the vacuum was 
released, the solvent of lowest polarity (ethyl acetate) poured quickly onto the adsorbent 
surface and the vacuum reapplied. The column was then sucked dry and the 
cyclopeptide fraction preadsorbed on silica-gel (1:3 ratio) was carefully introduced onto 
the surface of the packing (no vacuum). Enough solvent was used to completely cover 
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the top surface of the packing and vacuum applied gently to draw the sample into the 
packing. A solvent mixture consisting of EtOAc:acetic acid/water (1:1) was used as the 
starting mobile phase. Fifteen fractions (100 ml) were collected each time reducing the 
amount of EtOAc by 4.16% while keeping the acetic acid/water (1:1) constant. The last 
concentration used was 5:1. 
 
3.9.6. Analytical thin layer chromatography (TLC) 
Analytical thin layer chromatography was carried out on aluminum - backed 
plates of silica gel 60 F254 (5 x 10 cm, 0.25 mm layer thickness; E. Merck, Darmstadt, 
Germany) and after elution with a suitable solvent system, examined under UV light 
(254/366 nm). The plates were sprayed with 1% (w/v) vanillin-H2SO4 reagent (V-S, 
staining solution) (Wagner et al., 1984). Compounds were visualized after color 
development upon heating at 110ºC for 2 min. The developing solvent system consisted 
of a mixture of EtOAc, acetic acid and water (9:0.5:0.5). 
 
 
3.9.7. Purification by preparative thin layer chromatography (PTLC) 
Preparative thin layer chromatography of target fractions was performed on 
silica gel plates (EM, 60 F254, 20 cm × 20 cm, 0.25 mm thickness). Generally, the 
fraction was dissolved in the minimum amount of the selected developing solvent 
system and applied to the plate. The plate was developed, air-dried and observed under 
the UV light. The developed bands were scraped from the plate with the aid of a 
scraping knife and compounds were recovered from silica by repeated washes with the 
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solvent system.  The solvent system used for the separation of cyclopeptides by PTLC 
consisted of a mixture of EtOAc, acetic acid and water (9:0.5:0.5), developed 2-4 times. 
 
3.9.8.  High performance Liquid Chromatography-Photo Diode Array Detection-
 Mass Spectroscopy (HPLC-PDA-MS) analysis 
 HPLC analyses were performed by Mr. Greg Bishop (NRC-PBI) using a Waters 
Alliance 2695 chromatography system with inline degasser, coupled to a ZQ 2000 mass 
detector and a 2996 PDA, was used for analyses. Waters MassLynx v. 4.0 software was 
used for data acquisition and manipulation. The columns used were a Waters Symmetry 
RP C18 (150 × 2.1 mm i.d.; 3.5 μm), a Waters Sunfire RP C18 (150 × 2.1 mm i.d.; 3.5 
μm) or a Phenomenex (Torrance, CA, USA) Synergi MAX-RP 80A C12 (250 × 2.0 mm 
i.d.; 4 μm). The flow rate with the Waters columns was 0.2 mL/min, and with the 
Phenomenex column 0.15 mL/min. Columns were maintained at 35°C during runs. The 
binary solvent systems used were with solvent A, 0.12% acetic acid in 
10% acetonitrile (aq., v/v), and solvent B, 0.12% acetic acid in 100% acetonitrile. 
Gradients used were: (1) 0–3 min, 75% A–25% B; 3–25 min, 75% A–25% B to 50% A– 
50% B; 25– 28 min, 25% A–75% B to 100% B; 28–33 min, 100% B; and (2) 0–8 min, 
90% A–10% B; 8–31 min, 90% A–10% B to 50% A– 50% B; 31–33 min, 50% A–50% 
B to 100% B; 33–48 min, 100% B. Injection volumes of 5μL were typical. 
 Unless otherwise noted, the mass detector parameters (ESI−) were set to 
capillary (kV) 2.70, cone (V) −30 to −90.0 over a masss range of 400–1900, extractor 
(V) −3.50 and RF lens (V) −0.7. PAD was performed over the range 200– 400 nm, and 
saponins were monitored at 209 nm. 
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3.10. Stimulation of apoptosis using flow cytometry 
 Flow cytometry was performed at the University of Saskatchewan Cancer Centre 
Research Unit. Ms. Leah Deibert (NRC-PBI) performed assays as described below. 
 Three assays were used to determine if Segetoside H (MW 1448) could induce 
apoptosis in PC-3 and MDA-MB-231 cells: Dual Sensor: MitoCaspTM (Cell 
Technology), Vybrant® Apoptosis Assay Kit #2 (Molecular ProbesTM), and APO 
LOGIXTM Carboxyfluorescein Caspase 9 Detection Kit (Cell Technology). PC-3 cells 
were seeded in tissue culture flasks with regular growth medium and maintained under 
normal conditions. After cells had adhered, the tissue culture medium was replaced with 
medium containing Segetoside H dissolved in DMSO with the final concentration of 
DMSO not exceeding 0.05%. For each assay, a flask of untreated cells was grown in 
media containing the same amount of DMSO as in the Segetoside H treated samples. 
Following incubation under normal growth conditions for the specified time, cells were 
washed once with cold phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 
4.3 mM Na2HPO4·7H2O, 1.4 mM KH2PO4) and harvested as previously described. 
Assays were carried out according to instructions given in kits. All flow cytometry was 
performed using a Coulter Epics XL (Beckman). 
 Dual Sensor: MitoCaspTM  as performed by Ms. L. Deibert. 
 Following Segetoside H treatment, adherent and non-adherent cells were 
harvested and washed with cold PBS. Following centrifugation at 500 ¯ g for 5 min, 
cell pellets were resuspended in PBS at 3.3 ¯ 106 cells/mL. Cell suspension (300 μL) 
was mixed with 10 μL each of 30¯ Mitochondria Membrane Potential Dye and 30¯ 
Caspase 3/7 detection reagent. Following incubation for 60 min under normal growth 
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conditions, cells were washed twice with 1¯ wash buffer and resuspended in 0.5 mL 
1¯ wash buffer. Samples were analyzed by flow cytometry measuring the fluorescence 
emissions from 515 nm to 530 nm for caspase detection, and 574 nm to 600 nm for 
mitochondrial membrane potential detection. 
 Samples of purified saponins having MW 1278, 1422, 1464, 1448 and Quinoa 
saponin were provided by Dr. J. Balsevich (NRC-PBI). 
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CHAPTER 4 
RESULTS AND DISCUSSION 
 
Identification, isolation, structural determination, cytotoxic evaluation and 
mechanism of action of S. vaccaria L. saponins 
 
4.1. Evaluation of the cytotoxic activity of the methanol extracts of seed from 
 four varieties of Saponaria vaccaria L. on three human cancer cell lines 
 (WiDr, MDA-MB-231 and NCI-417) 
The cytotoxic activity of the methanol extracts from seed of Scott, Pink Beauty 
(PB), White Beauty (WB) and Mongolia (MG) were analysed in the MTT assay on the 
human cancer cell lines WiDr, MDA-MB-231 and NCI-417. The activity of 
commercially available seed extract “Wang Bu Liu Xing”, Quillaja saponin (QS) and 
Quinoa were also evaluated for comparative purposes. There was a dose-dependent 
reduction in saponin-induced cell killing, showing 100% cell death at the highest 
concentration tested (50 μg/mL). Figure 4.1 shows data for the methanol extract from 
seeds of the four S. vaccaria varieties. The highest sensitivity was observed with the 
human colon cancer cell line WiDr, and the extract from the Scott WT variety showed 
higher cytotoxicity when compared with those from PB, WB and MG. A similar 
response was observed with the extracts from WBLX and QS (Fig. 4.2). Quinoa extract 
did not show any activity. When the dose-response curves generated from all extracts 
were compared on each cell line individually, the cytotoxicity exerted by the Scott WT
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variety on WiDr and MDA-MB-231 was more evident (Fig. 4.3a and 4.3.b). It was also 
noticed the great variability in responses and minimal differences in cytotoxic activities 
by the extracts on the human lung cancer cell line NCI-417 (Fig. 4.3.c). The biological 
activities expressed as IC50 values of the seed extracts exerted against the three human 
cancer cell lines are presented in Tables 4.1, 4.2, and 4.3. These values were calculated 
from dose response curves generated by computer program MS Excel. 
IC50 is defined as the concentration of an extract or drug that is required for 50% 
inhibition of cell growth. A plant extract is regarded as cytotoxic if its IC50 value is less 
than 10 μg/mL (Jackson et al., 2000), and a pure compound is defined as cytotoxic if its 
IC50 value is less than 4 μg/mL (Fiebig et al., 1985). IC50 values shown herein were not 
based on the plant preparation, but on estimated saponin content of extract. The Scott 
WT variety showed the highest activity followed by the MG variety. PB and WB 
varieties showed similar results to the commercially available saponin extract. Quillaja 
saponin showed higher IC50 values (less toxic) than cow cockle plants, and quinoa did 
not show any activity at the highest concentration tested (50 μg/mL). It was later learned 
that the seeds of wild-type Scott variety contains a significantly greater titer of higher 
molecular weight saponins with a novel 3-O-trisaccharide structure, associated with the 
activities observed (Balsevich et al., 2006).  
While the Scott WT variety had the highest toxicity overall, the seed from the 
PB variety was used for the scale-up extractions due to greater availability and the 
observation that it contained the same saponins as Scott variety, albeit in different 
relative amounts.  
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Note: The 50% inhibitory concentration is the midpoint of the sigmoid curve. (n = 6). 
 
 
Figure 4.1. Inhibition induced by saponins present in the 70% MeOH seed extract of 
four varieties of Saponaria vaccaria L. (a) Scott, (b) Pink Beauty, (c) Mongolia and (d) 
White Beauty at five different concentrations (50, 25, 12.5, 6.25 and 3.13 μg/mL) on 
three human cancer cell lines.  
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Note: The 50% inhibitory concentration is the midpoint of the sigmoid curve (n = 6). 
 
 
Figure 4.2. Inhibition induced by saponins present in the 70% MeOH seed extract of a) 
Saponaria vaccaria L. (commercial extract Wang Bu Liu Xing) and b) Quillaja 
saponaria M. at five different concentrations (n = 6) on three human cancer cell lines. 
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Note: The 50% inhibitory concentration is the midpoint of the sigmoid curve. (n = 6). 
 
 
Figure 4.3. Mortality induced by saponins present in the 70% MeOH seed extract of 
four Saponaria vaccaria L. varieties (Scott, Pink Beauty, Mongolia and White Beauty); 
a commercial extracts from S. vaccaria seed (Wang Bu Liu Xing) and Quillaja 
saponaria M. on a) human colon cancer cell line WiDr, b) human breast cancer cell line 
MDA-MB-231, and c) human lung cancer cell line NCI-417.  
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Table 4.1.  IC50 values of extracts from four varieties of Saponaria vaccaria L. seed and 
from commercial extract Wang Bu Liu Xing, quillaja and quinoa saponins against the 
colon cancer cell line WiDr. 
 
 70% MeOH extract 
Cow cockle variety
IC50 (μg/mL)† 
Scott WT 3.80 ± 0.600* 
Pink Beauty 9.10 ± 0.300* 
Mongolia 7.65 ± 0.250* 
White Beauty 9.40 ± 1.100 ‡ 
Wang Bu Liu Xing 
(Botanicum brand) 
9.45 ± 0.950*‡ 
Quillaja saponin 17.9 ± 0.707 
Quinoa saponin > 50 
 
 
 
 
 
 
 
 
 
 
† Saponaria vaccaria L. IC50 values were based on estimated saponin content of the 
crude extract and expressed as mean ± S.D. (n = 6). Significant values are denoted by * 
for P < 0.05 in comparison to Quillaja extract. Significant values within Scott WT 
variety and the extracts from MG and WBLX are denoted by ‡ for P < 0.05 (t-test). 
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Table 4.2.  IC50 values of extracts from four varieties of Saponaria vaccaria L. seed and 
from commercial extract Wang Bu Liu Xing, quillaja and quinoa saponins against the 
breast cancer cell line MDA-MB-231. 
 
 70% MeOH extract 
Cow cockle variety
IC50 (μg/mL)† 
Scott WT 11.35 ± 1.250* 
Pink Beauty  18.40 ± 0.200 
Mongolia 16.80 ± 0.600* 
White Beauty  19.55 ± 0.050 
Wang Bu Liu Xing 
(Botanicum brand) 
19.40 ± 0.100 
Quillaja saponin 22.90 ± 1.131 
Quinoa saponin > 50 
 
 
 
 
 
 
 
 
 
 
† Saponaria vaccaria IC50 values were based on estimated saponin content of the crude 
extract and expressed as mean ± S.D. (n = 6). Significant values are denoted by * for P 
< 0.05 (t-test) in comparison to Quillaja extract. No significant differences were found 
within the other extracts tested for cytotoxic activity on MDA-MB-231. 
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Table 4.3.  IC50 values of extracts from four varieties of Saponaria vaccaria L. seed and 
from commercial extract Wang Bu Liu Xing, quillaja and quinoa saponins against the 
lung cancer cell line NCI-417. 
 
70% MeOH extract Cow cockle variety
IC50 (μg/mL)† 
Scott WT 12.55 ± 4.313 
 
Pink Beauty  17.75 ± 1.909 
Mongolia 15.15 ± 3.182 
White Beauty  18.25 ± 0.636 
Wang Bu Liu Xing 
(Botanicum brand) 18.65 ± 2.051 
Quillaja saponin 28.9 ± 9.899 
Quinoa saponin > 50 
 
 
 
 
 
 
 
 
 
 
 
† Saponaria vaccaria L. IC50 values were based on estimated saponin content of the 
crude extract and expressed as mean ± S.D. (n = 6). With the exception of Quinoa, no 
significant differences were found among the extracts tested for cytotoxic activity on 
NCI-417. 
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4.2. Saponin profile of the seed extracts of S. vaccaria L. 
 The methanol extracts from all four S. vaccaria varieties were analysed by 
HPLC-PDA-MS. Profiles of the seed extracts were found to contain the same saponins, 
albeit in different proportions. Figure 4.4 shows the PDA (λ = 209nm) of the section of 
the chromatogram (10-25 min) corresponding to saponins present in the methanol 
extract of Pink Beauty. Bisdesmosidic triterpene saponins Segetoside I (MW 1464) and 
Vaccaroside E (MW 1422) were readily identified by their molecular weights in the MS 
spectra obtained by single ion scanning (data not shown). It was observed that many 
saponins co-elute under one signal (peak), masking the actual number of saponins 
present in the extract.  
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Figure 4.4. HPLC chromatogram of total MeOH extract from Saponaria vaccaria L 
var. Pink Beauty. 
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4.3. Reverse phase column chromatography (RPCC), High Performance Liquid 
 Chromatography-Photo Diode Array Detection-Mass Spectrometry (HPLC-
 PDA-MS) and biological evaluation of fractions 
The methanol extract from 100 g de-fatted seed of S. vaccaria L. var. Pink 
Beauty was applied into glass column and 30-100 mL fractions were collected and 
analysed by HPLC-PDA-MS. It was observed that many of the fractions were a mixture 
of several saponins and that many signal peaks overlap, making the analytical process 
more complicated. Figure 4.5 shows a comparison of the LC-PDA profiles of the crude 
methanol extract (top) and two fractions (bottom) eluted from the column during the 
separation of compounds according to their different polarities.  
Major components of these fractions were identified (Table 4.4.) as a result of 
continuous fractionations and a better understanding on the metabolic profiling of S. 
vaccaria. 
Several known cyclopeptides such as segetalin A (8), segetalin B (9), and 
segetalin D, as well as some bisdesmosidic triterpene saponins (e.g. vaccaroside E, 
MW=1422; vaccaroside G, MW=1406; segetoside H, MW=1448; segetoside I, 
MW=1464) were readily identified by selected ion extraction of quasi-molecular ions 
from the total ion chromatogram (TIC) and confirmed by their mass spectra (MS). Many 
of the saponins had not been previously reported and remained to be elucidated. Using 
photodiode array (PDA) and single quadrupole electrospray mass detection (SQMS), a 
method for analysis and profiling of bisdesmosidic saponins in S. vaccaria was 
developed (Balsevich et al., 2006, see Appendix 1).  
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Figure 4.5. Liquid chromatography-Photo Diode Array profiles of the crude methanol 
extract (a) and two fractions (b, c) eluted from the column during the separation of 
compounds according to their different polarities. 
 
 
In summary, five known saponins, as well as twenty new quillaic acid and 
gypsogenin-type bisdesmosides were detected via mass spectral analysis. Five of these 
(MWs= 1538, 1554, 1580, 1596 and 1638) were tentatively identified as pentose 
homologues of known saponins, having an added xylose residue linked to the 3-O-
glucuronyl group (1 → 3) (Table 4.5). The quillaic acid-type bisdesmosidic saponins 
were classified in three Types according to the sugar chains as shown in Fig. 4.6. 
 67
The structures of triterpene saponins Vaccaroside E (PC 1422), Segetoside I (PC 
1464), Segetoside I + Acetate (PC 1506), New Saponin (PC 1596), Segetoside H (PC 
1448) and Vaccaroside JB (New Saponin PC 1526) are shown in Appendix 2. 
 
Table 4.4. Fractionation of cow cockle extract (Pink Beauty) on Supelco Discovery 
DSC-18Lt reverse phase packing (performed by J. Balsevich). 
 
Fraction 
No. 
% 
MeOH 
Yield and 
observations 
Main peaks (MS) 
1 0 4 g (sugars) --- 
2 10 0.7 g (sugars) --- 
3 10 --- --- 
4/5 15 --- --- 
6/7 25 --- --- 
8/9 25 ca. 100 mg MW 520 sucrose ester 
(dihydrocinnamate) 
10/11 30-35 226 mg, yellow MW 726 vaccarin 
12/13 40 yellow MW 726, MW 564 
14 45 87 mg, yellow MW 564, 904 
15/16 45-50 215 mg MW 484 segetalin B 
17/18 50-55 
19/20 55-60 
17-20 comb. 
540 mg 
MW 609 segetalin A + others 
 
21/22 60-65 328 mg MW 719 segetalin D + mono- and 
bisdesmosidic saponins 
23/24 70 380 mg Mainly monodesmosides + MW1464 
segetoside I 
25/26 80 1.2 g MW 1278 vaccaroside B + bisdesmosidic 
saponins 
27/28 80 280 mg Cryst. MW 1640, MW 1772; mother liq. 
Mainly MW 1448 
29/30 100 100 mg Not examined 
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Table 4.5. Bisdesmosidic saponins observed in Saponaria vaccaria L. var. Scott WT. 
Retention times were obtained by selected ion extraction from TIC of appropriate quasi-
molecular ion. Disaccharide = 3-O-β-D-Galp-(1→2)-β-D-GlcpA; trisaccharide = 3-O- β-
D-Xylp-(1→3)-[β-D-Galp-(1→2)]-β-D-GlcpA. 
 
[M-H]- 
m/z 
Aglycone 3-O-substituents Compound 
Fragment ions 
m/z 
Rt (min) 
(single run) 
1394 Quillaic acid Disaccharide Unknown 823, 485 10.48 
1406 Gypsogenin Disaccharide Vaccaroside G 807, 469 17.81 
1422 Quillaic acid Disaccharide Vaccaroside E 823, 485 13.55 
1436 Quillaic acid Disaccharide Unknown 823, 485 18.36 
1448 Gypsogenin Disaccharide Segetoside H 807, 469 22.07 
1464 Quillaic acid Disaccharide Segetoside I 823, 485 18.36 
1478 Quillaic acid Disaccharide Unknown 823, 485 23.59 
1506 Quillaic acid Disaccharide Segetoside I Ac 823, 485 20.87 
1526 Quillaic acid Trisaccharide Unknown 955, 485 11.27 
1538 Gypsogenin Trisaccharide New saponin 939, 469 17.58 
1554 Quillaic acid Trisaccharide New saponin 955, 485 13.52 
1556 Quillaic acid Disaccharide Unknown 823, 485 10.60 
1568 Quillaic acid Trisaccharide Unknown 955, 485 18.23 
1580 Gypsogenin Trisaccharide New saponin 939, 469 21.69 
1596 Quillaic acid Trisaccharide New saponin 955, 485 18.13 
1598 Quillaic acid Disaccharide Unknown 823, 485 17.91 
1610 Quillaic acid Trisaccharide Unknown 955, 485 23.27 
1626 Quillaic acid Trisaccharide New saponin 985, 485 17.51 
1638 Quillaic acid Trisaccharide New saponin 955, 485 20.52 
1640 Quillaic acid Disaccharide Unknown 823, 485 23.06 
1688 Quillaic acid Trisaccharide Unknown 955, 485 10.69 
1730 Quillaic acid Trisaccharide Unknown 955, 485 11.91 
1730 Quillaic acid Trisaccharide Unknown 955, 485 17.76 
1772 Quillaic acid Trisaccharide Unknown 955, 485 22.75 
1814 Quillaic acid Trisaccharide Unknown 955, 485 23.53 
Note: Table reproduced from Balsevich et al., 2006. 
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Legend: QA = quillaic acid, GLUR = glucopyranosiduronic acid, GAL = galactopyranose, XYL = 
xylopyranose, FUC = fucopyranose, ARA = arabinofuranose, RHA = rhamnopyranose, GLC = 
glucopyranose, Ac = acetate.  
 
 
 
 
Figure 4.6. Gross structures of quillaic acid-type bisdesmosidic triterpene saponins 
identified in Saponaria vaccaria L. 
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Legend: QA = quillaic acid, GLUR = glucopyranosiduronic acid, GAL = galactopyranose, XYL = 
xylopyranose, FUC = fucopyranose, ARA = arabinofuranose, RHA = rhamnopyranose, GLC = 
glucopyranose, Ac = acetate.  
 
Figure 4.6. (continued) Gross structures of quillaic acid-type bisdesmosidic triterpene 
saponins identified in Saponaria vaccaria L. 
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 All fractions collected from the RPCC separation were evaluated for their 
cytotoxic activity against three human cancer cell lines (colon, breast, and lung). Only 
saponin-containing fractions (from Fraction 15-16) showed moderate activities against 
the cancer cell lines tested. These fractions were tested at least three more times (n ≥ 9) 
and were also evaluated on the human fibroblast normal cell line CRL-2522 which was 
used as a control. 
 The effects of extracts were expressed by IC50 values calculated from dose 
response curves. Dose-response curves were established of selected fractions showing 
cytotoxic activity (Fractions 14 – 27-28). From these curves it is only evident the 
reduced activities of Fraction 14 and ML 27-28 on WiDr and MDA-MB-231 cell lines, 
as well as the moderate activity exerted by all fractions analysed on the human fibroblast 
normal cell line CRL-2522 (Fig. 4.7). 
 IC50 values are presented in Table 4.6 and results from each cell line tested are 
shown graphically in Figs. 4.8, 4.9, 4.10 and 4.11. 
 
 
 
 
 
 
 
 
 
 72
-20.0
0.0
20.0
40.0
60.0
80.0
100.0
120.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8
log concentration (μg/mL)
%
 m
or
ta
lit
y
F 14
F 15-16
F 17-20
F 21-22
F 23-24
F 25-26
Xtal 27-28
ML 27-28
Quillaja
a) WiDr 
-20.0
0.0
20.0
40.0
60.0
80.0
100.0
120.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8
log concentration (μg/mL)
%
 m
or
ta
lit
y
F 14
F 15-16
F 17-20
F 21-22
F 23-24
F 25-26
Xtal 27-28
ML 27-28
Quillaja
b) MDA-MB-231 
-20
0
20
40
60
80
100
120
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8
log concentration (μg/mL)
%
 m
or
ta
lit
y
F 14
F 15-16
F 17-20
F 21-22
F 23-24
F 25-26
Xtal 27-28
ML 27-28
Quillaja
c) NCI-417 
-20.0
0.0
20.0
40.0
60.0
80.0
100.0
120.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8
log concentration (μg/mL)
%
 m
or
ta
lit
y
F 15-16
F 17-20
F 21-22
F 23-24
F 25-26
Xtal 27-28
d) CRL-2522 
 
Note: The 50% inhibitory concentration is the midpoint of the sigmoid curve. (n ≥ 6). 
 
Figure 4.7. Mortality induced by fractions collected from the reverse phase 
chromatographic separation (RPCC) of a 70% MeOH seed extract from Saponaria 
vaccaria L. var. Pink Beauty on (a) human colon cancer cell line WiDr; (b) human 
breast cancer cell line MDA-MB-231; (c) human lung cancer cell line NCI-417; and (d) 
human fibroblast normal cell line CRL-2522. Standard deviations have been omitted for 
clarity. 
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Table 4.6. IC50 values of extracts and fractions from Saponaria vaccaria L. seed (pink 
beauty variety) tested in vitro using the MTT bioassay against three human cancer cell 
lines WiDr (colon), MDA-MB-231 (breast), NCI-417 (lung) and human fibroblast 
normal cell line CRL-2522. 
 
             Cell line 
 
Sample fraction 
WiDr 
(colon) 
MDA-MB-231
(breast) 
NCI-417 
(lung) 
CRL-2522 
(fibroblast) 
 IC50 (μg/mL)* IC50 (μg/mL)* IC50 (μg/mL)* IC50 (μg/mL)*
Fraction 3† > 50 μg/mL > 50 μg/mL > 50 μg/mL N/D 
Fraction 4 > 50 μg/mL > 50 μg/mL > 50 μg/mL N/D 
Fraction 6-7 > 50 μg/mL > 50 μg/mL > 50 μg/mL N/D 
Fraction 14‡ 46.15 ± 0.950 26.15 ± 16.350 > 50 μg/mL N/D 
Fraction 15-16‡ 8.70 ± 1.436 4.55 ± 2.257 17.87 ± 1.101 5.30 ± 0.200 
Fraction 17-20§ 11.25 ± 2.727 10.10 ± 4.168 22.63 ± 4.599 6.25 ± 0.050 
Fraction 21-22** 10.00 ± 1.994 10.72 ± 2.775 16.44 ± 2.796 3.60 ± 0.265 
Fraction 23-24†† 11.80 ± 3.336 9.50 ± 3.082 19.45 ± 3.793 7.70 ± 0.451 
Fraction 25-26†† 8.43 ± 2.229 6.65 ± 2.108 13.35 ± 2.233 5.03 ± 0.267 
Crystal fraction 
27-28‡‡ 
8.75 ± 2.249 12.28 ± 2.224 13.94 ± 1.898 4.67 ± 0.133 
ML 27-28§§ 12.80 ± 3.117 10.18 ± 2.996 17.30 ± 4.705 N/D 
Quillaja saponin 24.37 ± 7.347 28.25 ± 9.250 27.27 ± 6.886 N/D 
 
Note: The range of concentrations tested was 3.1 – 50 μg/mL. N/D = not determined 
    * Numbers represent the mean IC50 values ± S.E.M., n ≥ 6. 
    † Fraction 3 = eluted from the column with 20% MeOH;  
    ‡ Fractions 14-16 = mixture of polar and non-polar CP’s;  
    § Fractions 17-20 = mostly CP’s and some saponins;  
** Fractions 21-22 = mostly monodesmosidic saponins and segetalin D;  
  †† Fraction 23-26 = bisdesmosidic saponins;  
  ‡‡ Crystal fraction 27-28 = precipitate formed upon cooling of fraction 25-26;  
  §§ ML 27-28 = Soluble portion of fraction 27-28;  
Quillaja Saponin = 70% MeOH extract from commercially available extract (Sigma) 
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Note: IC50 values are expressed as mean ± S.E.M (n ≥ 6). Significant values within 
Fraction 14 and other RPCC fractions are denoted by * for P < 0.05 (t-test). No other 
significant differences were observed.  
 
 
 
Figure 4.8. Comparison of IC50 values of extracts and fractions from seed of Saponaria 
vaccaria L. (pink beauty variety) and commercially available saponin mixture from 
Quillaja saponaria (Sigma brand, control) tested in vitro using the MTT bioassay 
against the human colon cancer cell line WiDr. 
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Note: IC50 values are expressed as mean ± S.E.M (n ≥ 6). Significant value within 
Fraction 15-16 and Xtal 27-28 is denoted by * for P < 0.05 (t-test). No other significant 
differences were observed.  
 
Figure 4.9. Comparison of IC50 values of extracts and fractions from seed of Saponaria 
vaccaria L. (pink beauty variety) and commercially available saponin mixture from 
Quillaja saponaria (Sigma brand, control) tested in vitro using the MTT bioassay 
against the breast cancer cell line MDA-MB-231. 
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Note: IC50 values are expressed as mean ± S.E.M (n ≥ 6). No significant differences 
were found within any fraction tested for cytotoxic activity on NCI-417. 
 
Figure 4.10. Comparison of IC50 values of extracts and fractions from seed of 
Saponaria vaccaria L. (pink beauty variety) and commercially available saponin 
mixture from Quillaja saponaria (Sigma brand, control) tested in vitro using the MTT 
bioassay against the human lung cancer cell line NCI-417. 
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Figure 4.11. Comparison of IC50 values of six fractions from seed of Saponaria 
vaccaria L. (pink beauty variety) tested in vitro using the MTT bioassay against the 
human fibroblast normal cell line CRL-2522. 
 
 
All bisdesmosidic saponin-containing fractions (fractions 15-28) showed 
cytotoxic activity. Sugar, phenolic, and cyclic peptide-containing fractions (fractions 1-
14) did not show any cytotoxic activity in the MTT assay at the highest concentration 
tested (50 μg/mL). Fractions 14-20 were mostly cyclic peptide-containing fractions with 
traces of saponins, thus the activity observed.  
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 Although it is believed that there are significant differences in the cytotoxic 
responses of Fractions 15-16 and 25-26 relative to Quillaja saponin to the breast cancer 
cell line MDA-MB-231, these differences were not observed when the Student’s t-test 
analysis assuming unequal variances was employed. 
 The amount of cell response variation observed in the MTT assay has been 
attributed to cell variability from assay to assay. These variations can be observed in the 
following range of IC50 values of the three samples discussed above (Table 4.7). 
 
Table 4.7. IC50 values (μg/mL) obtained from dose-response curves of the RPCC 
Fractions 15-16, 25-26 and the 70% methanol extract from commercial quillaja extract 
on human breast cancer cell line MDA-MB-231. 
 
Fxn 15-16 Fxn 25-26 QS 
IC50 (μg/mL) 
0.2 3.0 19.0 
0.3 3.0 37.5 
0.5 10.2  
0.6 10.4  
2.0  
3.3  
14.4  
15.1  
 
 
Note: IC50 values represent the average of one independent experiment performed in 
triplicate. 
 
Saponin-containing fractions were further purified by successive column 
chromatographic separations. Fractions containing semi-pure saponins (80% +) were 
obtained and their molecular weights (MW) determined by HPLC-PDA-MS. The major 
compound with MW 1278 corresponded to the monodesmosidic saponin Vaccaroside B, 
and compounds with MW 1448 and 1464 corresponded to the bisdesmosidic saponins 
Segetoside H and Segetoside I, respectively. All three saponins were evaluated for 
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cytotoxic activity using the MTT assay on human cancer cell lines WiDr (colon), MDA-
MB-231 (breast) and NCI-417 (lung) as well as the human fibroblast normal cell line 
CRL-2522. Commercially available Kochia (fireweed) saponin (Kochia scoparia (L.) 
Roth, Chenopodiaceae) and horse chestnut (Aesculus hippocastanum L., 
Hippocastanaceae) triterpenic saponin mixture, β-escin, both containing structurally 
similar sapogenin as in S. vaccaria (oleanane type), were used as controls. It was 
interesting to notice that only the bisdesmosidic saponins showed high cytotoxicity, and 
that this activity was particularly enhanced against the breast cancer cell line MDA-MB-
231. Dose-response curves for the triterpene bisdesmosidic saponins Segetoside H (MW 
1448) and Segetoside I (MW 1464) were generated for calculation of IC50 values (Fig. 
4.12). 
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Figure 4.12. Inhibition induced by bisdesmosidic triterpene saponin a) Segetoside H 
(MW 1448) and b) Segetoside I (MW 1464) isolated from the seed of Saponaria 
vaccaria L. at six different concentrations on five human cell lines. (n ≥ 6). 
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The extract of the fruit of Kochia has been used as a traditional Oriental 
medicine for the treatment of several ailments (jaundice, edema, etc.), it is not reported 
to have any cytotoxic, antitumor or anticancer properties. It is also worth mentioning the 
negative results obtained from kochia saponin since the major constituents in the fruits 
are momordin Ic, an oleanolic acid oligoglycoside (monodesmosidic saponin), and 
oleanoic acid (Wen et al., 1995). β-Escin, another oleanane-type monodesmosidic 
saponin and the principal biologically active component of horse chestnut, showed 
moderately positive results. β-Escin has been mainly used for the treatment of venous 
insufficiency, diabetes, and as anti-inflammatory (Sirtori 2001; Matsuda et al., 1997), 
but no reports on antitumor or anticancer activity were found, however, escins are 
known to be highly hemolytic (Voutquenne et al., 2002; Ivanov et al., 1988) which may 
account in part for the observed cytotoxicity. IC50 values are reported in Table 4.8. 
 
Table 4.8. IC50 values (μg/mL) from the dose-response curves of monodesmosidic 
triterpene saponin Vaccaroside B, bisdesmosidic triterpene saponins Segetoside H and 
Segetoside I isolated from Saponaria vaccaria L. seed, Kochia saponin and horse 
chestnut β-escin saponin tested in vitro against the cancer cell lines WiDr, MDA-MB-
231, and NCI-417, and the normal fibroblast line CRL-2522 using the MTT bioassay. 
 
N/D = Data not calculated 
 WiDr MDA-MB-231 NCI-417 PC-3 CRL-2522 
Sample IC50 (μg/mL) 
Vaccaroside B 
(MW 1278) 
> 50 μg/mL > 50 μg/mL > 50 μg/mL N/D > 50 μg/mL 
Segetoside H 
(MW 1448) 
15.85 ± 0.495 1.26 ± 0.071 18.62 ± 2.333 11.749 ± 3.811 14.13 ± 1.414 
Segetoside I 
(MW 1464) 
16.70 ± 0.989 1.58 ± 0.636 19.75 ± 0.212 3.98 ± 1.414 3.98 ± 1.273 
Kochia saponin > 50 μg/mL > 50 μg/mL 44 N/D > 50 μg/mL 
β-escin 21 9.5 18 N/D 27 
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4.4. Purification of saponins by column chromatography (CC) using RP-
 Amberchrome® CG 300 chromatographic grade resin, their analysis by 
 HPLC-PDA-MS  and biological evaluation of fractions 
  In order to purify more of the bioactive bisdesmosidic saponins, 15 g of saponin 
mixture (SPM) was fractionated by column chromatography using Amberchrome resin 
CG-300S as the stationary phase. HPLC-PDA-MS analysis of the twenty-two fractions 
collected (CC-1 to CC-22) showed bisdesmosidic saponins starting from fraction 9. A 
detailed study on the saponin composition in each fraction was then performed (Table 
4.9). As expected, it was noticed that the nature of the saponins and their amounts varied 
from fraction to fraction. Fraction 9 showed a mixture of cyclopeptide Segetalin B 
(MW484) with at least five other saponins, being monodesmosidic saponin Vaccaroside 
B (MW 1278) the one in greatest abundance relative to the other saponins in the fraction 
(~20% saponin content). Cyclopeptide Segetalin A (MW 609) was found present in 
Fraction 12 along with Vaccaroside B and other bisdesmosidic saponins. All remaining 
fractions were mixtures of bisdesmosidic saponins. The total ion chromatograms (TIC) 
of fraction CC-12 and CC-16, and both the PDA and TIC of fraction CC-19 are shown 
below (Figs. 4.13, 4.14, and 4.15). CC-19 is also a mixture of bisdesmosidic saponins 
having vaccaroside G (MW 1406) as the major compound (67%). CC-19 showed 
interesting cytotoxic properties and was obtained in high yield (ca. 300 mg). The 
cytotoxic results will be discussed below. 
 
 
Fraction 
Saponin 
(MW 1538) 
Rt=20min 
Saponin 
(MW 1596) 
Rt=21min 
Vaccaroside G 
(MW 1406) 
Rt=26min 
Segetoside I 
(MW 1464) 
Rt=27min 
(Rt=21 min) 
Segetoside I Ac 
(MW 1506) 
Rt=30min 
Segetoside H 
(MW=1448 
Rt=31min 
CC- 9-10 --- --- --- --- --- --- 
CC-12 --- 10% --- 36% --- --- 
CC-13 --- 16% --- 60% --- --- 
CC-14 --- 23% --- 68% --- --- 
CC-15 --- 23% --- 58% --- --- 
CC-16 --- 23% traces 48% --- --- 
CC-17 traces 20%** 14%** 48% --- --- 
CC-18 7% --- 26% 17% 13% 9% 
CC-19 27% traces 67% 7% --- --- 
CC-20 16% --- 27% traces 16% --- 
CC-22 ---- --- 10% --- --- 69% 
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          Table 4.9.  Characterization  of  the major  compounds from fractions eluted from the chromatographic separation  of  
       saponin mixture (SPM)  by  HPLC-PDA-MS  analysis.  Saponins with  higher MW  (i.e. 1638, 1640, 1772)   
       are not shown. 
Fraction 
Segetalin B 
(MW 484) 
Rt=5min 
Segetalin A 
(MW609) 
Rt=8min 
Vaccaroside B 
(MW 1278) 
Rt=13min 
Saponin 
(MW 1526) 
Rt=14min 
Saponin 
(MW=1442) 
Rt=15min 
Saponin 
(MW=1554) 
Rt=16min 
Vaccaroside E 
(MW 1422) 
Rt=16min 
CC- 9-10 * --- 20% 9% 3% 4% 5% 
CC-12 --- * 10% 9% --- (          22%          )** 
CC-13 --- --- --- --- --- 6% 6% 
Note: Percentage values represent relative amounts to other saponins in the same fraction (expressed as Area %)     
 *present in significant amounts        **overlapping of peaks       
 
          Identified compounds with Retention times (Rt) below 20 min. 
 
 
 
 
 
 
 
          Identified compounds with Retention times (Rt) above 20 min.    
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Figure 4.13. Total ion chromatogram of fraction CC-12 showing the main identified 
saponins and cyclopeptide segetalin A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Total ion chromatogram of fraction CC-16 showing segetoside I, 
vaccaroside G, and a newly identified saponin, all overlapped under one signal. 
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Figure 4.15. HPLC-PDA-MS chromatogram of fraction CC-19 showing identified 
known and unknown saponins. 
 
 
 
All saponin containing fractions were tested for cytotoxic activity against the 
cancer cell lines WiDr, MDA-MB-231, NCI-417, and PC-3, and the human fibroblast 
normal cell line CRL-2522.  Dose-response curves of CC fractions against individual 
cell lines showed a consistent pattern of cytotoxic activities (Fig. 4.16).  Additionally, 
all saponin-containing fractions, but in particular fractions CC-18, CC-19, CC-20 and 
CC-21 showed enhanced cytotoxicity to human breast cancer cell line MDA-MB-231. 
These observations were confirmed when the dose-response curves of each individual 
fraction were compared against all cell lines (Fig. 4.17). 
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Figure 4.16. Inhibition induced by fractions collected from the chromatographic 
separation of a saponin mixture (SPM) from the seed of Saponaria vaccaria L. at 
different concentrations (n≥3) on human cancer cell lines (a) WiDr, colon;  (b) 
MDA-MB-231, breast; (c) NCI-417, lung; (d) PC-3, prostate; and (e) human normal 
fibroblast cell line CRL-2522. 
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Figure 4.17. Inhibition induced by individual fractions collected from the 
chromatographic separation of a saponin mixture (SPM) from the seed of Saponaria 
vaccaria L. at different concentrations (n≥3) on five human cell lines. 
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Figure 4.17. (Continued) Inhibition induced by individual fractions collected from the 
chromatographic separation of a saponin mixture (SPM) from the seed of Saponaria 
vaccaria L. at different concentrations (n≥3) on five human cell lines. 
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Figure 4.17. (Continued) Inhibition  induced by individual fractions collected from the 
chromatographic separation of a saponin mixture (SPM) from the seed of Saponaria 
vaccaria L. at different concentrations (n≥3) on five human cell lines. 
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The high cytotoxic activity (low IC50 values) exerted by the saponins over the 
breast cancer cell line MDA-MB-231 in comparison with the other cell lines is 
remarkable. While toxicity in PC-3 was also moderately high, values were similar to 
those from the normal fibroblast cell line CRL-2522. The other two cell lines WiDr and 
NCI-417 only showed cytotoxic results at concentrations that harmful (toxic) doses 
would be needed for the treatment of those forms of cancer. Cisplatin, an anticancer 
drug used for the treatment of a variety of tumors (metastatic testicular and ovarian 
tumors, advanced bladder carcinoma, breast cancer, head and neck carcinoma, lung 
carcinoma) was used as a positive control. It is noteworthy that the action of these 
saponins (or the mixture of them) on the breast cancer cell line is more toxic than the 
control cisplatin. 
 The results from this study also suggest that certain cell lines (WiDr, NCI) are 
more resistant to the cytotoxic action of the S. vaccaria bisdesmosidic saponins, whereas 
for others (MDA-MB-231, PC-3, and maybe CRL-2522), exposure to small amounts of 
these saponins can be lethal. IC50 values obtained from dose-response curves of all CC 
fractions and cisplatin are presented in Table 4.10, and graphically on Fig. 4.18. 
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 Table 4.10. IC50 values (μg/mL) obtained from a dose-response curve of semi-pure 
saponins extracted from Saponaria vaccaria L. seed, tested in vitro against the human 
cancer cell lines WiDr (colon), MDA-MB-231 (breast), NCI-417 (lung) and PC-3 
(prostate) and the human fibroblast normal cell line CRL-2522 using the MTT bioassay. 
 
 
 
               Cell line 
Sample 
WiDr MDA-MB-231 NCI-417 PC-3 CRL-2522
CC 9-10 8.8 1.8 32.4 5.2 7.4 
CC-11 26.9 2.4 30.2 5.0 5.9 
CC-12 9.1 1.5  21.9 4.9 5.5 
CC-13 9.1 1.8 18.1 4.3 5.0 
CC-14 13.2 1.3 20.0 5.1 5.2 
CC-15 13.6 1.8 19.3 4.1 6.3 
CC-16 16.6 3.2 21.4 5.9 8.2 
CC-18 5.9 0.9 15.6 2.5 3.6 
CC-19 4.5 0.9 16.8 2.7 3.6 
CC-20 4.2 0.9 14.2 2.5 2.7 
CC-21 15.2 1.3 17.1 3.0 3.3 
Cisplatin† 8.9 (2.7) 
26.9 
(8.1) 
12.0 
(3.6) 
9.4 
(2.8) 
11.8 
(3.6) 
 
Note: IC50 values for MDA-MB-231 were calculated using concentrations 
 between 0.6 – 50 μg/mL for accurate measurements. 
 † Cisplatin preparations are expressed in μM (μg/mL) 
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Note: Significant values for CC-fraction treatments are denoted by * for P < 0.05 (t-test) 
in comparison to Cisplatin. (n≥3). 
 
 
Figure 4.18. Comparison of IC50 values of fractions from the chromatographic 
separation of Saponaria vaccaria L. saponin extract on four human cancer cell lines 
WiDr (colon), MDA-MB-231 (breast), NCI-417 (lung), PC-3 (prostate), and the human 
fibroblast normal cell line CRL-2522. 
 
 
4.5. Evaluation of selected drugs to be used as potential positive controls in the 
 MTT assay 
In order to select commercially available drugs to be used as positive controls for 
the bioassays besides cisplatin, solutions of verapamil, pimozide, a 1:1 mixture of 
verapamil and pimozide, and the anticancer drugs 5-fluorouracil (5-FU) and vinblastine 
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(VLB) were prepared and exposed to WiDr, MDA-MB-231, NCI-417 and CRL 2522 
cell lines. Results are shown in Table 4.11. 
 
Table 4.11. IC50 values (μM) of four commercially available drugs against three human 
cancer cell lines WiDr, MDA-MB-231, NCI-417 and the human fibroblast normal cell 
line CRL-2522. 
 
              Cell line 
 Drug 
WiDr 
(colon) 
MDA-MB-231 
(breast) 
NCI-417 
(lung) 
CRL-2522 
(fibroblast) 
 IC50 (μM ) 
Verapamil 90.67 ± 7.001 >120 >120 N/D 
Pimozide 8.84 ± 1.702 20.22 ± 2.068 13.46 ± 2.060 18.23 ± 0.722 
Verapamil + 
pimozide 
9.40 ± 1.457 17.19 ± 1.855 15.60 ± 2.139 N/D 
5-Fluorouracil† 17.03 ± 3.714 12.50 ± 0.100 47.77 ± 25.292 >120 
Vinblastine‡ < 3.75 < 3.75 < 3.75 29.83 ± 11.26 
 < 3.75 < 3.75 < 0.004  
 < 0.004 < 0.004   
         
Note: The values expressed represent the mean ± S.D. (n≥3). N/D = data not calculated. 
         † Some results showed IC50 values higher than max. concentration tested (120 μM) 
         ‡ Vinblastine results are discussed below 
 
 
Pimozide has been used in the management of chronic schizophrenic patients 
(Rathbone and McMonagle, 2000). It has also been shown in our laboratory that the 
synergistic effect of a potent calmodulin antagonist (pimozide) with a calcium channel 
blocker (verapamil) inhibited proliferation of human colon cancer cell lines using the 
human tumor clonogenic assay (Wong, 1986). However, using the MTT method, the 
mixture of verapamil and pimozide showed results corresponding to pimozide alone 
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since verapamil did not show any cytotoxicity. Pimozide toxicity was greater against 
WiDr (IC50 = 8.84 μM or 4.1 μg/mL), then against NCI-417 (IC50 value 13.46 μM or 6.2 
μg/mL) and least toxic against MDA-MB-231 (IC50 = 20.22 μM or 9.3 μg/mL). The IC50 
value for pimozide against the normal fibroblast cell line was 18.23 μM or 8.4 μg/mL. 5-
FU showed intriguing data since results were quite contradictory. We speculate that 
preparation and storage conditions of the drug were not suitable, and optimal conditions 
need to be investigated. Most intriguing were the results obtained from VLB since at the 
range of concentrations tested (3.75–120 μM), only the two highest ones showed a dose-
response mortality of cells. Due to these results, a bioassay was conducted using very 
low concentrations of this drug, showing that even at the lowest concentration tested 
(4 nM) results were still the same (Table 4.12). Dose-response graphs were generated 
for comparative purposes (Fig. 4.19). Examination under the microscope showed that 
drug treated cells were still alive but not dividing. This would suggest that below the 
toxic concentration (approximately 60 μM) cells were still viable, perhaps in the “resting 
state”. This was an unexpected dose-response result and no similar or related data was 
found in the literature, other than a study suggesting that tumor cells suspended in tissue 
culture medium can alter tumor cell kinetics causing an effect in tumor sensitivity to cell 
cycle specific drugs (i.e. vinca alkaloids), but not to non-cycle specific drugs (Durkin et 
al., 1979). The normal cell line CRL-2522 did respond in a typical dose-response 
fashion for the three highest concentrations allowing the calculation of an IC50 value of 
29.83 μM (27.1 μg/mL). However, at concentrations of 30μM and below, cell viability 
did not seem to be affected. Further examination of the literature and experiments are 
needed in order to rationalize these results.  
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Table 4.12. Percentage mortality of three cancer cell lines WiDr, MDA-MB-231, and 
NCI-417, and a normal fibroblast cell line CRL-2522 when tested against various 
concentrations of vinblastine. 
 
 
Percentage 
Mortality (%) 
 
Concentration  
(μM) WiDr 
(colon) 
MDA-MB-241 
(lung) 
NCI-417 
(lung) 
CRL-2522 
(fibroblast) 
120 96.8 91.9 92.0 94.9 
60 82.9 81.7 97.8 54.5 
30 63.6 64.3 91.0 37.2 
15 58.7 57.2 96.4 34.2 
7.5 63.4 56.9 91.8 37.0 
3.75 63.1 56.8 87.3 33.9 
1.875 59.6 53.9 81.1  
0.938 59.5 47.8 87.1  
0.469 58.5 51.6 85.5  
0.234 56.4 50.9 83.7  
0.117 58.6 47.2 75.3  
0.059 57.5 50.0 83.9  
0.029 59.0 48.4 82.9  
0.015 60.1 50.0 81.9  
0.007 59.2 38.7 73.7  
0.004 58.4 41.3 77.7  
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Figure 4.19. Mortality induced by Vinblastine at different concentrations (n=3) on 
human cancer cell lines WiDr (colon), MDA-MB-231 (breast), NCI-417 (lung) and 
human fibroblast normal cell line CRL-2522. 
 
 
4.6. Chemical modifications of saponins in relation to their cytotoxic activity 
Structural changes of secondary metabolites by chemical modifications are 
commonplace in the chemistry laboratory in an attempt to improve the physical and/or 
biological activities of the original leads. 
Three minor chemical modifications on the structure of saponin-containing 
fraction CC-19 were performed: a sodium borohydride (NaBH4) reduction of the 
aldehydic group; a methylation reaction with diazomethane (CH2N2) on the carboxylic 
group of the C-3-O-glucuronic acid, and a de-acetylation reaction with 
 96
(mono)ethanolamine (MEA) (Fig. 4.20). Careful study of the HPLC-PDA-MS of the 
reaction products provided enough information to account for the percentage conversion 
of CC-19 into the corresponding final products. 
 
 
 
 
 
 
CC-19 
(mainly bisdesmosidic saponins)
1) NaBH4 reduction
 
 
 
 
 
 
 
 
 
Figure 4.20. A study of the structure-activity relationships of saponins with sodium 
borohydride (NaBH4), diazomethane (CH2N2) and (mono)ethanolamine (MEA). 
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4.6.1. Sodium borohydride reduction 
 
 
    
            
R C H
O
R CH2 OH
NaBH4
Rt
(MW + 2)
CC-19 (40 mg) was dissolved in 50% MeOH (5 mL) with heat and sonication. 
After saponins were dissolved, the solution was cooled down in an ice/water bath and 
NaBH4 (5 mg) was immediately added. Solution was then stirred at room temperature 
for 30 min., quenched with acetone (Me2CO), and then diluted to a concentration of 
20% MeOH. The reaction product was filtered through a C18 cartridge and saponins 
were retrieved with 100% MeOH after pre-washes with water and 20% MeOH. 
HPLC-PDA-MS analysis of the reaction product showed approximately 50% 
conversion of the aldehyde into the alcohol (data not shown). In a consequent reduction 
reaction, reduction of saponins was achieved with excess NaBH4 and longer reaction 
times (approx. 2h). 
 
4.6.2. Methylation reaction with diazomethane (CH2N2) 
 
R C OH
O
R C
O
O
CH2NH2
Et2O (MW + 14)
CH3
 
 
 
 Diazomethane was prepared from Diazald (Aldrich Chemical Co., Milwaukee, 
Wisc.) using their Diazald Kit. CC-19 (35 mg) was dissolved in 90% MeOH (2.5 mL) 
and diazomethane (approx. 1 mL) was added until the yellow colour of excess 
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diazomethane persisted for 15 min. The reaction was kept at room temperature until 
CH2N2 evaporated.  
HPLC-PDA-MS analysis (Fig. 4.21) showed three signals (bottom 
chromatogram) at Rt 25.62, 26.27, 26.53 and 27.22 min corresponding to the methylated 
saponins 1420 (1406+14), 1478 (1464+14) and 1552 m/z (1538+14), respectively. 
 
IRE, CC-19 + CH2N2, Nov 25_05, Sunfire 150 mm, 35 deg, 30-90 CV
 
 
Figure 4.21. Comparison of chromatograms of saponin mixture CC-19 with its 
corresponding methylated products. a, b, c, and d correspond to the methylated saponins 
1420 (1406+14), 1478 (1464+14) and 1552 m/z (1538+14), respectively. 
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4.6.3. De-acetylation reaction with (mono)ethanolamine (MEA) 
 
    
    R OHC
O
CH3OR
OH
NH2
Rt (MW - 42)
 
CC-19 (40 mg) was dissolved in 80% MeOH (30 mL) and adjusted to pH 9 with 
MEA. Citric acid (4 mg) was then added and the solution was refluxed for 2 h. The 
reaction mixture was then neutralized with tartaric acid and diluted with excess water 
(20 mL). A chromatographic separation was performed using a pre-packed 200 mg C18 
column and washing the mixture first with water, and retrieving the saponins with 100% 
MeOH. The MeOH extract was then evaporated until dryness and analysed by HPLC-
PDA-MS. 
Figure 4.22 shows the chromatograms generated by HPLC-PDA-MS. Using 
single ion extraction from the total ion chromatogram it was possible to identify the de-
acetylated saponins. Table 4.13 shows the assignation of peaks as compared to the 
parent saponin. 
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IRE, NaOH total deacetylation , Dec 21_05, Sunfire 150mm, 35 deg, 30-90 CV
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Figure 4.22. LC-MS chromatogram of the de-acetylation reaction of saponin-containing 
fraction CC-19. Peaks labeled a–i correspond to de-acetylated saponins which showed a 
decrease of m/z 42 or 84 from the parent saponin, corresponding to the loss of either one 
or two acetyl groups, respectively. 
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Table 4.13. Possible relationship of de-acetylated reaction products from corresponding 
parent saponin. 
 
 
Peak Rt (min) MW Parent saponin (MW) Corresponds to 
a 13.03 1380 1422 − 1 Ac or 
1464 − 2 Ac 
Vaccaroside E or 
Segetoside I 
b 14.63 1688 1772 − 2 Ac Unknown 
c 16.47 1688 1772 − 2 Ac Unknown 
d 17.03 1394 1478 − 2 Ac  Unknown 
e 17.43 1364 1406 − 1 Ac Vaccaroside G 
f 19.50 1554 1638 − 2 Ac New saponin 
g 19.95 1422 1464 − 1 Ac or 
1506 − 2 Ac 
Segetoside I or 
Segetoside I Acetate
h 24.27 1538* Not detected in CC-19 New saponin 
i 25.10 1406 * 1406 or 
1448 – 1 Ac 
Vaccaroside G or 
Segetoside H 
 
*The corresponding parent saponins were not detected in CC-19 or they were probably 
masked under a larger signal. 
 
The cytotoxic activity of the chemically modified saponins was tested on WiDr, 
MDA-MB-231, NCI-417, PC-3 and CRL-2522 cell lines using CC-19 as a control for 
comparison. Dose-response curves were generated and are presented in Fig. 4.23 and 
Fig. 4.24. Fraction CC-19 showed the highest cytotoxicity overall, while the chemical 
derivatization products showed varied results depending on the cell line. When the 
responses of each individual fraction were compared on all cell lines, it was evident the 
enhanced cytotoxicity exerted on MDA-MB-231 (breast) over the other cell lines. 
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Note: error bars have been omitted for clarity. 
 
Figure 4.23. Inhibition induced by bisdesmosidic saponin-enriched fraction CC-19 and 
corresponding chemical derivatization products on (a) human colon cancer cell line 
WiDr, (b) human breast cancer cell line MDA-MB-231, (c) human lung cancer cell line 
NCI-417, (d) human prostate cancer cell line PC-3, and (e) human fibroblast normal cell 
line CRL-2522. 
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Note: error bars have been omitted for clarity. 
 
Figure 4.24. Inhibition induced by the reaction products of the bisdesmosidic saponin-
enriched fraction CC-19 upon treatment with diazomethane (CH2N2) on five human cell 
lines. 
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 In summary, CC-19 alone is more potent than its corresponding modified 
structures on all cell lines studied, but CC-19 showed no enhanced selectivity on any 
cell line, including control CRL-2522. However, all chemically modified products 
showed enhanced selectivity on MDA-MB-231 and the de-acetylated product also 
showed enhanced selectivity on PC-3 (all compared to CRL-2522). 
 Additional cytotoxic activities were calculated for CC-19, its chemically 
modified structures and cisplatin (positive control) on human breast cancer cell line 
Hs578 T and its normal counterpart Hs578 BST (Fig. 4.25). 
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Figure 4.25. Inhibition induced by bisdesmosidic saponin-enriched fraction CC-19, its 
corresponding chemical modified structures and cisplatin on (a) human breast cancer 
cell line Hs578 T and (b) human breast normal cell line Hs578 BST. 
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 IC50 values were generated from all dose-response curves (Table 4.14, Fig. 4.26). 
As observed previously, cytotoxic activity of the corresponding reaction products was 
not enhanced when compared with unmodified CC-19. However, IC50 values of CRL-
2522, mainly from the de-acetylated and the methylated saponins, were significantly 
increased (less toxic). The other two cell lines (WiDr and NCI-417) did not show any 
significant differences. When comparing the dose-response graphs from Fig. 4.25, with 
the exception of the de-acetylated fraction, fraction CC-19 and its modified structures 
showed enhanced cytotoxicity over the cancer cell line. This difference in cytotoxic 
activity was not observed with cisplatin. 
 
Table 4.14. IC50 values from reaction products from the structural modifications of CC-
19 against four cancer cell lines WiDr (colon), MDA-MB-231 (breast), NCI-417 (lung) 
and PC-3 (prostate) and human fibroblast normal cell line CRL-2522. (n≥6). 
Fraction WiDr MDA-MB 231 NCI-417 PC-3 
CC-19 6.66 ± 6.877a 1.26 ± 0.341cdef 16.00k 2.88 ± 1.996
CC-19 + NaBH4 
(reduction) 
12.60 ± 0.300ab 1.90cg 21.00 ± 0.707l 7.20 ± 2.970
CC-19 + MEA 
(de-acetylation) 
14.57 ± 5.060 2.23 ± 0.208dhi 19.80 ± 1.273m 4.80 ± 0.141
CC-19 + CH2N2 
(methylation) 
9.14 ± 9.597 1.68 ± 0.250ej 20.65 ± 1.061n 7.13 ± 5.601
Cisplatin 8.14 ± 8.444b 8.68 ± 4.382fghij 4.44 ± 4.487klmn 3.42 ± 2.086
Fraction CRL-2522 Hs578 T Hs578 BST  
CC-19 3.66 ± 0.588p 3.13 ± 1.613q 13.20 ± 2.858u  
CC-19 + NaBH4 
(reduction) 
5.80 ± 0.707 4.70 ± 0.212r 15.20 ± 0.849vx  
CC-19 + MEA 
(de-acetylation) 
8.90p 13.60 ± 1.131qs 18.70 ± 0.778vy  
CC-19 + CH2N2 
(methylation) 
8.48 ± 3.859 3.50 ± 0.424t 14.70 ± 1.131z  
Cisplatin 7.33 ± 3.733 1.20 ± 0.789rst 1.25 ± 0.789uxyz  
Note: IC50 values are expressed as mean ± S.E.M (n ≥ 6). Same letters within 
columns denote mean values which are significantly different (t-test  P = 0.05) 
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Figure 4.26. Cytotoxic comparison (IC50 values) of saponin-containing fraction CC-19 
with its chemically modified reaction products (reduced, de-acetylated and methylated 
saponins) and cisplatin on five human cancer cell lines (WiDr, colon; MDA-MB-231, 
breast; NCI-417, lung; PC-3, prostate and Hs578 T, breast) and two human normal cell 
lines (CRL-2522, fibroblast and Hs578 BST, breast). 
 
 
 
4.7. Preliminary studies of the mechanism of action (MOA) of Saponaria 
 vaccaria saponins 
It has been reported that apoptosis or programmed cell death (PCD) is the 
mechanism of action of many biologically active saponins extracted from other plant 
species (Haddad et al., 2004; Hsu et al., 2004; Yanamandra et al., 2003; etc.). 
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In order to study the MOA of S. vaccaria saponins, nuclear staining of the breast 
cancer cells with propidium iodide (PI) and Hoechst 33342 was performed. Physical 
differences in size or morphology, disruption of cell membrane, or the presence of 
apoptotic bodies revealed by the staining of the nucleus in saponin treated cancer cells 
would suggest apoptosis as the MOA of these saponins. 
PI intercalates into double-stranded nucleic acids. It is excluded by viable cells, 
but can penetrate cell membranes of dying or dead cells. Once the dye is bound to 
nucleic acids, its fluorescence is enhanced 20-30 fold. On the other hand, Hoechst 33342 
DNA staining is a UV-excitable nucleic acid stain readily taken up by all cells. Its blue 
fluorescence is particularly bright in the condensed nuclei of apoptotic cells.  
Saponin mixture CC-19 at four different concentrations (3, 10, 25 and 30 μg/mL) 
was used against MDA-MB-231 (breast cancer cell line) at different incubation times 
(0-48 h) and cells were then observed under a fluorescent microscope. The anticancer 
drug and apoptotic inducer cisplatin was used as a positive control, while the non-ionic 
surfactant Triton-X was used as the negative control. 
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4.7.1. Fluorescence microscopy studies 
 Microscopy studies were performed at the Plant Biotechnology Institute by Ms. 
Leah Deibert. Diagrams and photos were prepared by Dr. J. Balsevich. Control cells 
were carefully studied under the fluorescence and phase contrast microscope for 
morphology and staining patterns. All cells showed uniformity in these two aspects. A 
picture of the MDA-MB-231 cells stained with PI is shown in Fig. 4.27. 
 
 
 
 
 
 
 
 
 CONTROL
Phase contrastPI
 
Figure 4.27. MDA-MB-231 cells used as control and treated with propidium iodide. No 
irregularities in morphology or size were detected. Photo courtesy of  J. Balsevich. 
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 Triton-X showed disruption of membrane integrity and cell death at all 
incubation times. No difference in fluorescence was detected among the cells (Fig. 
4.28). 
 
 
 
 
 
 
 
 
 
 
 
Phase contrast Hoechst 33342 
 
 
 
Figure 4.28. MDA-MB-231 cells treated with triton-X and stained with Hoechst 33342 
after 4h of incubation. Cells were all dead. Photo courtesy of  J. Balsevich. 
  
 
 Cisplatin presented clear features of apoptosis at 24 and 48 h incubation times 
with cell disruption and shrinkage as well as apoptotic bodies and blebs. The bright 
fluorescence in some cells corresponded to the morphological disturbances observed 
under a phase contrast microscope (Fig. 4.29).  
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 a) Cisplatin treated MDA-MB-231 cells – 24h   Hoechst 33342 stained 
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B
Phase contrastHoechst 33342 
 
 
 
 
 
 
 
b) MDA-MB-231Cells treated with Cisplatin – 48h 
 
Figure 4.29. Cisplatin treated MDA-MB-231 cells stained with a) Hoechst 33342 after 
24h of incubation, and b) propidium iodide after 48 h of incubation. Cells show the 
characteristic features of apoptosis such as nuclei condensation (brighter blue or red), 
blebbing and cell shrinkage. Photo courtesy of  J. Balsevich. 
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Saponin mixture CC-19 treated cells showed apoptotic features with a 
remarkable reduction in cell number per plate. It was noticed that at early incubation 
times (4-6 h) and using very low concentrations (3 μg/mL), cells were already showing 
differences in morphology and size as compared with “normal” cells. Normal cells were 
elongated, and the stained nuclei showed uniform fluorescence. Cells undergoing 
apoptosis were smaller, fluorescence was accentuated in the nuclei, and fragmentation, 
blebs and apoptotic bodies were observed throughout. Figures 4.30 and 4.31 show the 
saponin-treated cells at 0, 6 and 12 h, stained with PI and Hoechst 33342, respectively. 
The above mentioned differences are most noticeable at higher concentrations (10 and 
25 μg/mL) (Figure 4.32).  
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Saponaria saponin, 
3 μg/ml – 6h
Saponaria saponin, 
3 μg/ml – 0h
PI Phase contrast
 
Figure 4.30. MDA-MB-231 cells treated with Saponaria saponin at a concentration of 3 
μg/mL at 0 and 6 h of incubation and upon treatment with propidium iodide. Arrows 
point toward apoptotic cells. Photo courtesy of  J. Balsevich. 
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MDA-MB-231 treated with Saponaria saponin – 3 μg/ml, 12h, stained with Hoechst 33342
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Figure 4.31. MDA-MB-231 cells treated with Saponaria saponin at a concentration of 3 
μg/mL after 12 h of incubation and upon treatment with Hoechst 33342. Some cells 
undergoing apoptosis were labeled A – F. Photo courtesy of  J. Balsevich. 
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Figure 4.32. Comparison of untreated MDA-MB-231 cells after 10 h of incubation with 
corresponding Saponaria saponin treated cells at concentrations of 10 and 25 μg/mL. 
Photo courtesy of  J. Balsevich. 
 
 
 Prostate cancer cells PC-3, breast cancer cells MDA-MB-231, and normal 
fibroblast cells CRL-2522 stained with Hoechst 33342 following a 24 hr treatment with 
7 μM Segetoside H (MW 1448) showed nuclear changes characteristic of apoptotic cells 
(Fig. 4.33). Apoptotic nuclei have highly condensed chromatin, often in crescent shapes 
around the periphery of the nucleus. 
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a) CRL-2522- Untreated b) CRL-2522- 24hr, 14μM Saponin MW 1448
d) PC-3- 24hr, 7uM PC1448 c) PC-3 - Untreated 
 e) MDA-MB-231 - Untreated f) MDA-MB-231- 24hr, 14uM PC1448 
 
 
 
 
 
 
Figure 4.33. Fluorescent microscopy of Hoechst 33342 stained nuclei in untreated 
(a,c,e) and PC1448 treated (b,d,f) CRL-2522 (a,b), PC-3 (c,d) and MDA-MB-231 (e,f) 
cells. Red arrows show nuclear changes characteristic of apoptotic cells. Photo courtesy 
of  J. Balsevich. 
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4.8. Stimulation of apoptosis by Saponaria vaccaria L. saponins 
 The following section describes the results from flow cytometry experiments on 
Saponaria saponins performed by Ms. Leah Deibert under the supervision of Dr. John 
Balsevich (NRC-PBI) and with technical assistance of Ms. Donna Dunlop (Dept. of 
Pharmacology, U of S). It is included in this dissertation to demonstrate current results 
on apoptosis as the MOA of Saponaria saponins as well as to exemplify some of the 
recent work done on Saponaria vaccaria L. 
 
4.8.1. Stimulation of apoptosis in human prostate cancer cells (PC-3) by 
 Segetoside H (MW 1448) 
 A time course study from 0 to 20 hrs was conducted with PC-3 cells treated with 
14 μM Segetoside H and analyzed using the Dual Sensor:MitoCaspTM. Results that 
demonstrate a significant increase in the cells with caspase 3/7 activity and 
concomitantly a dramatic increase in cells with decreased mitochondrial membrane 
potential are shown in Table 4.15 and Fig. 4.34 below. 
 In comparison to untreated PC-3 cells, there was a progressive time dependent 
increase representing approximately a doubling of the cells with measurable caspase 3/7 
activity over the 20 hr exposure period. Additionally, there was about a 20 fold increase, 
(4.5 % to 94.1 %) of cells with a decreased mitochondrial membrane potential following 
treatment with Segetoside H. A highly significant impact was observed after just five 
hours exposure. 
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Table 4.15. Apoptosis measured in PC-3 cells treated with 14 μM Segetoside H for 20 
hrs using the Dual Sensor: MitoCaspTM Assay. 
 
14 μM Segetoside H Cells with caspase 3/7activity (%) 
Cells with decreased mitochondrial
membrane potential (%) 
Untreated 24.6 4.5 
05 hr 13.0 38.0 
10 hr 29.2 72.5 
15 hr 42.9 89.4 
20 hr 57.2 94.1 
 
  
 The results shown in Table 4.15 are shown graphically in Fig. 4.34. The upper 
left hand frame of the figure shows the condition of PC-3 cells at the beginning of the 
experiment. Mitochondrial membrane potential is presented on the y axis and Caspase 
3/7 activity on the X axis. At time zero of the experiment the large majority of PC-3 
cells showed a healthy mitochondrial membrane potential above 101 and a modest 
number of cell displayed Caspase 3/7 activity. After only five hours of exposure to 
Segetoside H there was a rapid increase in the numbers of cells with decreased 
mitochondrial membrane potential. Further exposure times, (frames 3-5) showed the 
vast majority of cells with low mitochondrial membrane potential and Capsase 3/7 
activity indicating onset of apoptosis. 
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 Figure 4.34. Apoptosis measured in PC-3 cells treated with 14 μM Segetoside H (MW 
1448) for various times using the Dual Sensor: MitoCaspTM Assay. 
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 A similar set of experiments was conducted to testing a range of concentrations 
of Segetoside H (from 7 - 17 μM). Following treatment of PC-3 cells with Segetoside H 
for 26 hours, a concentration dependant increase in apoptotic cells was observed (Table 
4.16). The largest increase in caspase 3/7 activity was with cells treated with 10 μM 
Segetoside H however, all treated cells showed dramatic increases (an 8 fold increase) in 
caspase 3/7 activity even at 7 μM, the lowest concentration tested. The greatest change 
in cells with decreased mitochondrial membrane potential occurred with 14 μM 
Segetoside H however, again all treated cells showed large increases even at the lowest 
concentration tested. 
 
Table 4.16. Apoptosis in PC-3 cells treated with various concentrations of Segetoside H 
for 26h measured by The Dual Sensor: MitoCaspTM Assay. 
 
 
Segetoside H 
concentration (μM) 
Cells with caspase 3/7
activity (%) 
Cells with decreased mitochondrial
membrane potential (%) 
Untreated 10.1 2.8 
7 77.8 24.8 
10 86.2 30.8 
14 84.0 52.0 
17 77.7 41.9 
 
 The results shown in Table 4.16 are shown graphically in Fig. 4.35. As in Fig. 
4.34, the upper left hand frame of the figure shows the condition of PC-3 cells at the 
beginning of the experiment. Mitochondrial membrane potential is presented on the y 
axis and Caspase 3/7 activity on the X axis. At time zero of the experiment the large 
majority of PC-3 cells showed a healthy mitochondrial membrane potential above 101 
and a modest number of cell displayed Caspase 3/7 activity. After exposure of PC-3 
cells  to  Segetoside  H at  all  concentrations  (7, 10, 14, 17 μM),  there  was  a dramatic 
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Figure 4.35. Apoptosis measured in PC-3 cells treated with various concentrations of 
Segetoside H for 26h using The Dual Sensor: MitoCaspTM Assay. 
 121
increase in the number of cells displaying low mitochondrial membrane potential and 
increased levels of caspase 3/7 indicating the induction of apoptosis. A second time 
course study was conducted to measure apoptosis in PC-3 cells treated with 14 μM 
Segetoside H for various times. The Vybrant® Apoptosis Assay Kit #2 was used to 
assess apoptosis and results shown in Table 4.17 below demonstrate a three fold 
increase in Annexin V positive cells, when compared to untreated PC-3 cells, following 
a 24 hr treatment with Segetoside H. 
 
Table 4.17. Apoptosis in PC-3 cells treated with 14 μM Segetoside H for various times 
measured using the Vybrant® Apoptosis Assay Kit #2. 
 
14 μM Segetoside H Annexin-V positive cells 
(%) 
Untreated 11.3 
06 hr 12.4 
16 hr 28.3 
24 hr 34.7 
 
 Further evidence that Segetoside H stimulates apoptosis was evident from the 
detection of caspase 9 activity using the APO LOGIXTM Carboxyfluorescein Caspase 9 
Detection Kit. 
 As above, one set of experiments provided a time course study of Segetoside H 
over an extended 40 hr time period. Following treatment of PC-3 cells with 14 μM 
Segetoside H for various times, the APO LOGIXTM Carboxyfluorescein Caspase 9 
Detection Kit was used to measure apoptosis (Table 4.18). Segetoside H treatment 
caused an increase in PC-3 cells with caspase 9 activity. The largest increase was seen at 
20 hours again showing a three fold increase in PC-3 cells showing caspase 9 activity 
than in untreated cells. 
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Table 4.18. Apoptosis in PC-3 cells treated with 14 μM Segetoside H for various times 
measured using the APO LOGIXTM Carboxyfluorescein Caspase 9 Detection Kit. 
 
 
14 μM Segetoside H Caspase 9 positive cells 
(%) 
Untreated 8.5 
10 hr 37.7 
15 hr 44.2 
20 hr 48.0 
40 hr 29.4 
 
  
These results are shown graphically in Fig. 4.36 below. The figures show the significant 
increase in cells expressing Caspase 9 activity in as little as a few hours after exposure 
to Segetoside H. 
 A final concentration range experiment was conducted with PC-3 cells treated 
with Segetoside H for 20 hours at concentrations ranging from 7–17 μM (Table 4.19). 
The number of cells with caspase 9 activity increased with Segetoside H concentration 
up to 14 μM, at which the cells showed a four fold increase compared to untreated PC-3 
cells. As shown above all treated cells regardless of Segetoside H concentration showed 
large increases in caspase 9 activity. 
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Figure 4.36. Apoptosis measured in PC-3 cells treated with 14 μM Segetoside H for 
various times using the APO LOGIXTM Carboxyfluorescein Caspase 9 Detection Kit. 
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Table 4.19. Apoptosis in PC-3 cells treated with various concentrations of Segetoside H 
for 20 hr measured using the APO LOGIXTM Carboxyfluorescein Caspase 9 Detection 
Kit. 
 
Segetoside H concentration
(μM) 
Caspase 9 positive cells 
(%) 
Untreated 13.2 
7 47.7 
10 73.9 
14 75.3 
17 65.6 
 
 These results are shown graphically in Fig. 4.37 below. The figures show the 
significant increase in cells expressing caspase 9 activity with all concentrations of 
Segetoside H treatments. The optimal concentration appears to be in the 10–15 μM 
range. 
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Figure 4.37. Apoptosis measured in PC-3 cells following a 20 hr treatment with various 
concentrations of Segetoside H using the APO LOGIXTM Carboxyfluorescein Caspase 9 
Detection Kit. 
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4.8.2. Stimulation of apoptosis in human breast cancer cells (MDA-MB-231) by 
 Segetoside H (MW 1448) 
 MDA-MB-231 cells were treated with Segetoside H and assayed for apoptosis as 
previously described for PC-3 cells. 
 Following treatment with 14 μM Segetoside H for various times, MDA-MB-231 
cells were assessed for apoptotic activity using the Vybrant® Apoptosis Assay Kit #2. 
The results are shown in Table 4.20 and Fig. 4.38. A 2.7 fold increase in Annexin V 
positive cells, compared to untreated cells was seen after just 12 hr exposure to 
Segetoside H. These results are shown graphically in Fig 4.38. A shift in cell position in 
the diagram to the right and upwards indicates Annexin-V binding to phosphoserine 
residues external to the plasmalemma. The externalization of phosphoserine only occurs 
when cells have entered apoptosis. 
 
 
Table 4.20. Apoptosis in MDA-MB-231 cells treated with 14 μM Segetoside H for 
various times measured using the Vybrant® Apoptosis Assay Kit #2. 
 
 
14 μM Segetoside H Annexin-V positive cells 
(%) 
Untreated 17.1 
12 hr 46.3 
24 hr 37.9 
48 hr 37.9 
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Figure 4.38. Apoptosis in MDA-MB-231 cells treated with 14 μM Segetoside H for 
various times measured using the Vybrant® Apoptosis Assay Kit #2. 
 
 
 Additionally, MDA-MB-231 cells treated with 14 μM Segetoside H for various 
times were analyzed for apoptotic activity using the APO LOGIXTM Carboxyfluorescein 
Caspase 9 Detection Kit. Results are shown below in Table 4.21. Cells treated with 
Segetoside H showed an increased number with caspase 9 activity compared to 
untreated cells, in as little as 10 hrs. The maximum effect was a 2.5 fold increase in cells 
with caspase 9 activity after a 40 hr exposure to Segetoside H. These results shown 
 128
graphically in Fig 4.39 below again show the rapid rise in caspase 9 activity after cells 
are exposed to Segetoside H indicating cells are undergoing apoptosis. 
 
Table 4.21. Apoptosis in MDA-MB-231 cells treated with 14 μM Segetoside H for 
various times measured using the APO LOGIXTM Carboxyfluorescein Caspase 9 
Detection Kit. 
 
14 μM Segetoside H Caspase 9 positive cells 
(%) 
Untreated 16.6 
10 hr 25.0 
15 hr 31.6 
20 hr 32.5 
40 hr 41.6 
 
  
 Results are shown graphically in Fig. 4.39 below. The increase in numbers of the 
Caspase positive cells can be easily seen within ten hours exposure to Segetoside H. 
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Figure 4.39. Apoptosis in MDA-MB-231 cells treated with 14 μM Segetoside H for 
various times measured using the APO LOGIXTM Carboxyfluorescein Caspase 9 
Detection Kit. 
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4.8.3. Failure of Segetoside H (MW 1448) to stimulate apoptosis in human 
fibroblast normal cells (CRL-2522) 
 CRL-2522 cells were treated with Segetoside H and assayed for apoptosis as 
described above for PC-3 cells. 
 CRL-2522 cells were treated with 14 μM Segetoside H for various times and 
analyzed using the Dual Sensor:MitoCaspTM Assay. Results are shown in Table 4.22. 
and diagrammatically in Fig. 4.40 below. 
 Exposure of CRL-2522 cells to Segetoside H, even over prolonged times, 
showed no increase in cells with lowered mitochondrial membrane potential. 
Additionally, there was no evidence of the increase in Caspase 3/7 activity until the time 
in culture is extended and cultures are aging. These observations support the view that 
Segetoside H at 14 μM concentration had no significant effect on apoptosis in normal 
fibroblast cells. 
 
Table 4.22. Apoptosis in human fibroblast normal cells (CRL-2522) cells treated with 
14 μM Segetoside H for various times measured using the Dual Sensor: MitoCaspTM 
Assay. 
 
 
14 μM Segetoside H Cells with caspase 3/7activity (%) 
Cells with decreased mitochondrial
membrane potential (%) 
Untreated 3.1 1.9 
10 hr 3.7 1.4 
20 hr 5.5 1.4 
30 hr 32.8 0.8 
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Figure 4.40. Apoptosis in human fibroblast normal cells (CRL-2522) treated with 14 
μM Segetoside H for various times measured using the Dual Sensor: MitoCaspTM 
Assay. 
 
  
 These results shown graphically in Fig. 4.40 demonstrate that Segetoside H 
neither resulted in an increase in cells with reduced mitochondrial membrane potential 
nor an increase in cells expressing caspase 3/7 activity until the cultures were advanced 
in age. 
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  This result was confirmed by the Vybrant® Apoptosis Assay . CRL-2522 cells 
were treated with 14 μM Segetoside H for various times, the Vybrant® Apoptosis Assay 
Kit #2 was used to measure apoptosis as shown in Table 4.23 and Fig. 4.41 below. No 
meaningful changes in the number of CRL-2522 cells showing Annexin V staining 
following Segetoside H treatment were evident. 
 
Table 4.23. Apoptosis in human fibroblast normal cells (CRL-2522) treated with 14 μM 
Segetoside H for various times measured using the Vybrant® Apoptosis Assay Kit #2. 
 
 
14 μM Segetoside H Annexin-V positive cells 
(%) 
Untreated 13.5 
10 hr 17.2 
20 hr 9.3 
40 hr 18.2 
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Figure 4.41. Apoptosis in CRL-2522 cells treated with 14 μM Segetoside H for various 
times measured using the Vybrant® Apoptosis Assay Kit #2. 
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 A still further indication that Segetoside H does not stimulate apoptosis in 
normal fibroblast CRL-2522 cells was obtained using the APO LOGIXTM 
Carboxyfluorescein caspase 9 Detection Kit. Results from treatment of CRL-2522 cells 
with 14 μM Segetoside H for various times are shown in Table 4.24 and Fig. 4.42 
below. No increase in Caspase 9 positive cells was observed following a 10 to 40 hr 
treatment with Segetoside H. 
 
 
Table 4.24. Apoptosis in CRL-2522 cells treated with 14 μM Segetoside H for various 
times measured using the APO LOGIXTM Carboxyfluorescein Caspase 9 Detection Kit. 
 
 
14 μM Segetoside H Caspase 9 positive cells 
(%) 
Untreated 8.9 
10 hr 15.9 
20 hr 10.6 
40 hr 9.5 
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Figure 4.42. Apoptosis in human fibroblast normal cells (CRL-2522) treated with 14 
μM Segetoside H for various times measured using the APO LOGIXTM 
Carboxyfluorescein Caspase 9 Detection Kit. 
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4.8.4. Stimulation of apoptosis in human prostate cancer cells (PC-3) by 
 Segetoside I (MW 1464) 
 The ability of Segetoside I to induce apoptosis in PC-3 cells was tested using 
apoptosis assays described above. PC-3 cells were treated with Segetoside I using 
methods described for PC1448. 
 PC-3 cells treated with 7 μM Segetoside I for various times were analyzed using 
the Dual Sensor: MitoCaspTM Assay. Results are shown in Table 4.25 and Fig. 4.43 
below. Exposure to Segetoside I at a concentration of 7 μM induced apoptosis in PC-3 
cells in a time dependent fashion. Increases in apoptotic activity were apparent after 
only 10 hrs and increased dramatically thereafter. After exposure of PC-3 cells to 7 μM 
Segetoside I for 30 hr, the number of cells with caspase 3/7 activity increased four fold 
whereas cells with decreased mitochondrial membrane potential increased more than ten 
fold. 
 
Table 4.25. Apoptosis in human prostate cancer cells (PC-3) treated with 7 μM 
Segetoside I for various times measured using the Dual Sensor: MitoCaspTM Assay. 
 
 
7 μM Segetoside I Cells with caspase 3/7activity (%) 
Cells with decreased mitochondrial
membrane potential (%) 
Untreated 9.0 1.8 
10 hr 12.2 5.1 
20 hr 40.1 21.4 
30 hr 54.6 51.2 
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Figure 4.43. Apoptosis in human prostate cancer cells (PC-3) treated with 7 μM 
Segetoside I for various times measured using the Dual Sensor: MitoCaspTM Assay. 
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 This strong induction of apoptosis by Segetoside I at a concentration of 7 μM 
suggested that lower concentrations may also be effective. A series of decreasing 
concentrations of Segetoside I (1.75-7 μM) were tested for 26 hr using the Dual Sensor: 
MitoCaspTM Assay, shown in Table 4.26 and Fig. 4.44 below. The results how clearly 
the induction of apoptosis with all concentrations tested, but with significant effect at 
concentrations of 3.5 μM or higher. 
 
Table 4.26. Apoptosis in human prostate cancer cells (PC-3) treated with various 
concentrations of Segetoside I for 26 hr measured using the Dual Sensor: MitoCaspTM 
Assay. 
 
Segetoside I 
concentration (μM) 
Cells with caspase 3/7
activity (%) 
Cells with decreased mitochondrial
membrane potential (%) 
Untreated 7.8 1.7 
1.75 8.5 3.2 
3.50 40.4 14.8 
5.25 49.5 20.3 
7.00 59.4 24.1 
 
 
 These results are shown graphically in Fig 4.44 below. An increase in Capase 
3/7 activity and an increase in the number of cells with reduced mitochondrial 
membrane potential are shown in a dose dependent fashion. A concentration of only 3.5 
μM Segetoside I was capable of significant induction of apoptosis. 
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 Figure 4.44. Apoptosis in human prostate cancer cells (PC-3) treated with various 
concentrations of Segetoside I for 26h measured using the Dual Sensor: MitoCaspTM 
Assay. 
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 These results were confirmed by the Vybrant® Apoptosis Assay Kit #2 used to 
measure apoptosis in PC-3 cells treated with 7 μM or 14 μM Segetoside I for various 
times as shown in Table 4.27 and 4.28 and Fig 4.45 below. PC-3 cells showed a three to 
six fold increase in Annexin V positive cells, when compared to untreated PC-3 cells, 
following a 30 hr treatment with Segetoside I. 
 
Table 4.27. Apoptosis measured in human prostate cancer cells (PC-3) treated with 7 
μM Segetoside I for various times measured using the Vybrant® Apoptosis Assay Kit 
#2. 
 
7 μM Segetoside I Annexin-V positive cells 
(%) 
Untreated 12.4 
12 hr 15.0 
24 hr 28.5 
36 hr 38.0 
 
 
 
 
Table 4.28. Apoptosis measured in human prostate cancer cells (PC-3) treated with 14 
μM Segetoside I for various times measured using the Vybrant® Apoptosis Assay Kit 
#2. 
 
14 μM Segetoside I Annexin-V positive cells 
(%) 
Untreated 8.5 
10 hr 11.5 
20 hr 28.9 
40 hr 49.4 
 
 
 
 These results are shown graphically in Fig. 4.45 below. 
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Figure 4.45. Apoptosis in human prostate cancer cells (PC-3) treated with 7 μM 
Segetoside I for various times measured using the Vybrant® Apoptosis Assay Kit #2. 
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4.8.5. Stimulation of apoptosis in human breast cancer cells (MDA-MB-231) by 
 Segetoside I (MW 1464) 
 
 MDA-MB-231 breast cancer cells were treated with Segetoside I as previously 
described for Segetoside H. Apoptosis assays were performed as described above. 
 Following treatment of MDA-MB-231 cells with 3.5 μM Segetoside I for 
various times, the Dual Sensor: MitoCaspTM Assay was used to measure apoptosis as 
shown in Table 4.29 and Fig 4.46 below. Segetoside I was able to induce apoptosis in 
MDA-MB-231 cells at a concentration of 3.5 μM within ten hours. After exposure of 
PC-3 cells to 3.5 μM Segetoside I for 30 hr, the number of cells with caspase 3/7 
activity increased by two fold, whereas the number of cells with reduced mitochondrial 
membrane potential increased eight fold.  
 
Table 4.29. Apoptosis measured in human breast cancer cells (MDA-MB-231) treated 
with 3.5 μM Segetoside I for various times using the Dual Sensor: MitoCaspTM Assay. 
 
 
3.5 μM Segetoside I Cells with caspase 3/7activity (%) 
Cells with decreased mitochondrial
membrane potential (%) 
Untreated 15.0 6.6 
10 hr 20.0 19.9 
20 hr 27.5 51.5 
30 hr 29.1 52.0 
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 Figure 4.46. Apoptosis in human breast cancer cells (MDA-MB-231) treated with 3.5 
μM Segetoside I for various times measured using the Dual Sensor:MitoCaspTM Assay. 
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These results were confirmed by treatment of MDA-MB-231 cells with 7 μM 
Segetoside I for various times using the Vybrant® Apoptosis Assay Kit #2. Results are 
shown in Table 4.30 and Fig. 4.47 below. After a 36 hr exposure to Segetoside I, there 
was a 2-3 fold increase in Annexin V positive cells compared to untreated cells. 
 
 
Table 4.30. Apoptosis in human breast cancer cells (MDA-MB-231) treated with 7 μM 
Segetoside I for various times measured using the Vybrant® Apoptosis Assay Kit #2. 
 
7 μM Segetoside I Annexin-V positive cells 
(%) 
Untreated 17.2 
12 hr 28.8 
24 hr 39.7 
36 hr 49.3 
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Figure 4.47. Apoptosis in human breast cancer cells (MDA-MB-231) treated with 7 μM 
Segetoside I for various times measured using the Vybrant® Apoptosis Assay Kit #2. 
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4.8.6. Failure of Segetoside I (MW 1464) to stimulate apoptosis in human 
fibroblast normal cells (CRL-2522) 
 Human fibroblast normal cell (CRL-2522) were treated with Segetoside I as 
previously described for Segetoside H. Apoptosis assays were carried out as described 
above. 
 The Dual Sensor: MitoCaspTM Assay was used to analyze CRL-2522 cells 
treated with 7 μM Segetoside I for various times as shown in Table 4.31 and Fig. 4.48 
below. Segetoside I had a minimal effect on CRL-2522 cells. There was a modest 
increase in cells with caspase 3/7 activity compared to untreated CRL-2522 cells; 
however such increases are expected during the aging of the cultures. Essentially no 
changes in cells with decreased mitochondrial membrane potential were detected. 
 
Table 4.31. Apoptosis in human fibroblast normal cells (CRL-2522) treated with 7 μM 
Segetoside I for various times measured using the Dual Sensor: MitoCaspTM Assay. 
 
7 μM Segetoside I Cells with caspase 3/7activity (%) 
Cells with decreased mitochondrial
membrane potential (%) 
Untreated 2.7 3.9 
10 hr 3.2 4.4 
20 hr 11.7 4.4 
30 hr 16.9 5.1 
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Figure 4.48. Apoptosis in human fibroblast normal cells (CRL-2522) treated with 7 μM 
Segetoside I for various times measured using the Dual Sensor:MitoCaspTM Assay. 
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 These results were confirmed with the Vybrant® Apoptosis Assay Kit #2. 
Following treatment with 7 μM Segetoside I for various times, the results in Table 4.32 
and Fig. 4.49 below show that Segetoside I had little effect on CRL-2522 cells. The 
percent of Annexin V positive cells increased only modestly after a 30 hr exposure. 
 
 
Table 4.32. Apoptosis in human fibroblast normal cells (CRL-2522) treated with 7 μM 
Segetoside I for various times measured using the Vybrant® Apoptosis Assay Kit #2. 
 
 
7 μM Segetoside I Annexin-V positive cells 
(%) 
Untreated 6.9 
10 hr 6.0 
20 hr 8.4 
30 hr 10.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149
  
Figure 4.49. Apoptosis in human fibroblast normal cells (CRL-2522) treated with 7 μM 
Segetoside I for various times measured using the Vybrant® Apoptosis Assay Kit #2. 
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4.9. Purification and cytotoxic evaluation of cyclopeptides from the seeds of S. 
 vaccaria L. 
 During the exercise of purification of fractions from the methanol extracts of 
cow cockle seeds, three known cyclopeptides (segetalin A, B and D) and a new one, 
tentatively named segetalin I, were purified.  
Cyclopeptide-enriched fractions were obtained as shown in section 3.8.5. 
Cyclopeptides were purified from the diethyl ether (Et2O) insoluble fraction ‘CP 
A,B,D+’ by vacuum liquid chromatography (VLC). Five-grams of this fraction (5g) 
were fractionated by VLC. Fifteen 100 mL fractions were collected, aliquots were 
analysed by HPLC-PDA-MS, and crystal pure cyclopeptides segetalin A and B, 80% 
pure segetalin D and a new cyclopeptide, tentatively named segetalin I, were purified by 
consecutive preparative thin layer chromatography (PTLC) using a mixture of 
EtOAc:acetic acid:water (9:0.5:0.5, 4×). A chromatogram of the cyclopeptide-enriched 
fraction ‘CP A,B,D+’s is shown below (Fig. 4.50). 
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MW 724 
MW 484 MW 609 
Seg. I 
Seg. B 
Seg. A 
MW 719 
Seg. D 
PDA 
ES- 
 
Figure 4.50. Cyclic peptide-containing fraction showing a mixture of segetalin A, B, D, 
and newly identified segetalin I. 
 
The tentative structure of segetalin I was determined to be cyclo(Gly1-Pro2-Tyr3-
Tyr4-Pro5-Phe6) with a MW of 724.3208 (Fig. 4.51). Segetalin I has not been previously 
reported from any plant species. 
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 (77) 
Segetalin I (77). Amorphous off-white solid; [α]D −3.0°(c 1.1; H2O); UV (MeOH): λmax 
276, 283 nm; IR bands (KBr): 3400, 2996, 1680, 1574, 1418, 1136, 1043 cm−1.  
MS (ESI+): see Fig. 4.12; MS (ESI-): m/z: 723 [M-H]-, 511, 430, 414, 212. 
HRMS molecular weight determination: calcd. for C39H44N6O8: 724.3220; found: 
724.3208. 
 
Figure 4.51. Structure of segetalin I (77), chemical analysis and diagnostic fragments 
observed in its mass spectrum (ESI+).   
 
 
Pure and semi-pure cyclopeptides were also evaluated for cytotoxic activity on 
five cancer cell lines and two normal lines (Table 4.33), although it was previously 
reported that CP containing fractions did not show any activity (Table 4.6). 
Purified cyclopeptides did not show any activity at the highest concentration 
tested (50 μg/mL).  
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Table 4.33. IC50 values (μg/mL) of cyclic peptides from cow cockle seeds (Saponaria 
vaccaria L.) tested in vitro on five cancer cell lines (WiDr, colon; MDA-MB-231, 
 WiDr‡ 
MDA-MB- 
‡ NCI-417
‡ PC-3‡ 
CRL- 
§
breast; NCI-417, lung; PC-3, prostate; and Hs578T, breast) and two normal cell lines 
(CRL-2522, fibroblast and Hs578BST, breast) using the MTT bioassay. Cisplatin was 
used as a positive control. 
 
231  2522  
 IC50 (μg/ mL) 
Segetalin A >50.0 >50.0 >50.0 >50.0 >50.0 
Segetalin B NS  † † † † †
NEW Segetalin I 
>50.0 >50.0 >  > >50.0 
2 1  3 3 3
NS  NS  NS  NS  
(MW 724) 
50.0 50.0 
Cisplatin .0 μM 1.7 μM .5 μM .7 μM .7 μM 
 
 Hs578T‡ Hs578BST§    
NEW Segetalin I 
(MW 724) 
>50.0 >50.0    
 
 NS = Not soluble  
iDr (colon), MDA-MB 231 (breast), NCI-417 (lung), PC-3 
2 (fibroblast), Hs578BST (breast) 
†
‡ Cancer cell lines: W
(prostate), Hs578T (breast) 
§ Normal cell lines: CRL 252
 
 154
CHAPTER 5 
CONCLUSIONS AND FUTURE WORK 
 
5.1. Conclusions 
 This thesis work was part of a continuing interdisciplinary collaborative project 
between the University of Saskatchewan (Department of Pharmacology, College of 
Medicine) and the National Research Council of Canada-Plant Biotechnology Institute 
in Saskatoon. The main objective of this study was to investigate the biological activities 
of Saponaria vaccaria seed components particularly for their antitumor effects.  
 Initial agronomic studies showed that Saponaria vaccaria, a member of the Pink 
(carnation) family, grows well on the Canadian prairies and produced large quantities of 
seed that contains significant amounts of triterpene saponins. Subsequent studies on the 
saponin composition of four varieties of S. vaccaria collected from different sources 
showed that the bisdesmosidic saponins present in the seed were all similar albeit in 
different quantity. This supports other studies that have demonstrated that plants of the 
same species grown under different conditions (weather, soil, height, etc.) do not 
necessary follow a unique metabolic profile. 
 Chromatographic separation techniques were applied for the fractionation and 
purification of saponins and cyclopeptides and were implemented to provide enough 
purified fractions for analysis and cytotoxic studies. Although the new saponin 
compounds were not completely purified, a methodology for the identification of known
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and unknown triterpene saponins from S. vaccaria according to their fragmentation 
patterns using LC-MS-PDA was developed. This was a major finding that led to the 
identification of fourteen novel 3-O-trisaccharide saponins and seven new 3-O-
disaccharides in addition to the previously reported 3-O-disaccharide saponins. This is 
the first time that 3-O-trisaccharide saponins are reported in S. vaccaria. As a result, a 
distinctive pattern was established that allowed the arrangement of all detected quillaja-
type saponins into 3 types of families (Type I, Type II and Type III). 
 The cytotoxic activities of the triterpenoid saponin-containing fractions and the 
partially purified triterpenoid saponins isolated from S. vaccaria seed on four human 
cancer cell lines MDA-MB-231 (breast), PC-3 (prostate), WiDr (colon), and NCI-417 
(lung) was established based on the 50 % inhibitory concentration (IC50). The highest 
cytotoxicity obtained from the MTT assays from the seed extract of the ‘Scott’ variety 
may be attributed to its higher titer of 3-O-trisaccharide saponins in comparison with the 
other three varieties studied. When partially purified fractions eluted from the column 
chromatography separations of the seed methanol extract were evaluated for their 
cytotoxicity on the cancer cells, results showed that only the bisdesmosidic saponin-
containing fractions possessed cytotoxic activity. The sugars-, phenolics-, 
cyclopeptides- and monodesmosidic saponins-containing fractions were not cytotoxic 
even at the highest concentrations tested (50 μg/mL). When the bisdesmosidic saponin-
containing fractions were evaluated against the human fibroblast normal cell line CRL-
2522, moderate cytotoxicity was also observed. However, the enhanced selectivity 
observed to the human breast cancer cell line MDA-MB-231 and to the human prostate 
cancer cell line PC-3 suggests a potentially enhanced therapeutic index. The partially 
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purified (80%) triterpene bisdesmosidic saponins showed similar cytotoxic activities 
than the less purified saponin-enriched fractions also suggesting that saponin structure 
might not be a limiting factor for the observed cytotoxic activity.  
 It was interesting noticing that most of the fractions tested showed increased 
inhibition of cells at the lowest concentrations tested (1.6 μg/mL or lower). This effect, 
referred to as hormesis, is a common or important effect that has not been fully 
established. Although the idea that low dose effects may be different is accepted, it is 
still questionable that the low dose effect is positive. It has however been suggested that 
decreasing the dose not only produces quantitative changes in the response being 
measured but also qualitative changes. Although hormesis does not follow the standard 
linear-dose response model commonly accepted, several studies have been set to 
determine whether the concept of hormesis is valid, as well as biologically and 
toxicologically significant (Calabrese, 2004). 
 Due to the difficulty in the purification and isolation of individual saponins due 
to their close structural homology, chemical derivatizations were used to change both 
the saponin selectivity and IC50 values. Thus, semisynthesis was used to modify some of 
these components. The finding that these derivatized fractions were less active suggests 
that nature may have found the most active substances in evolution. 
 Preliminary histological studies showed that saponin-induced apoptosis occurs at 
a low dose and early incubation stage (~ 6 h). Stimulation of apoptosis by semi-purified 
bisdesmosidic saponins Segetoside H (MW 1448) and Segetoside I (MW 1464) on 
cancer cell lines MDA-MB-231 (breast) and PC-3 (prostate) was further studied and 
confirmed by flow cytometry. Selective cytotoxicity to cancer cell lines over the normal 
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cell line CRL-2522 (fibroblast) was remarkable since both saponins failed to induce 
apoptosis in the normal cell line. 
 A further contribution in the phytochemical identification of this plant was the 
isolation and identification of a number of cyclopeptides i.e. Segetalin A, B and new 
Segetalin I.  Although these compounds did not show any activity against the cancer cell 
lines tested, cyclopeptides are known bioactive compounds which are of considerable 
research value. 
 In summary, we propose the triterpene bisdesmosidic saponins from the seed of 
Saponaria vaccaria as a new type of drug with potential antitumor/anticancer activity 
due to their ability to induce apoptosis in vitro in human cancer cell lines at low 
concentrations. Additionally, uses of other saponaria-derived compounds 
(cyclopeptides, phenolics) may provide useful tools in the development of additional 
medicinal uses. These compounds are extracted from a plant that can be easily cultivated 
in the Canadian Prairies using conventional farm machinery. 
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5.2. Future Work 
 
 Following the investigations described in this dissertation, a number of projects 
 could be taken up, involving:  
• Further purification of bisdesmosidic saponins from the seed of Saponaria 
vaccaria by the use of diverse chromatographic techniques; 
• Evaluation of the cytotoxic activity on a larger panel of cancer cell lines; 
• Evaluation of toxicity of purified saponins in outbred mice in order to obtain 
LD50 values;  
• Administration of one or more saponin-containing formulations of unknown 
efficacy to tumor-bearing mice and monitoring and measurement of tumor 
growth; 
• Formulation studies of saponins with conventional anticancer agents, or as 
adjuvants; 
• Additionally reference chemotherapeutic agents (positive control) and negative 
controls to be similarly administered and maintained; 
• Studies on the biological properties of cyclopeptides isolated from S. vaccaria. 
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Abstract: A high-performance liquid chromatographic method using photodiode array and single quadrupole electrospray mass
detection for analysis and profiling of bisdesmosidic saponins in Saponaria vaccaria seed was developed. Profiles of seed extract
from three different plant sources were obtained and found to contain the same saponins, albeit in different proportions. Several
known saponins were identified by selected ion extraction of quasi-molecular ions from the total ion chromatogram and confirmed
by their mass spectra. Application of high cone voltages afforded mass spectra containing key diagnostic fragments and relatively
strong singly charged quasi-molecular ions. In addition to previously identified saponins, several new quillaic acid and gypsogenin
bisdesmosides could be detected via mass spectral analysis. Five of these were tentatively identified as pentose homologues of
known saponins, having an added xylosyl residue linked to the 3-O-glucuronyl group (1 → 3). The stereochemistry and identity of
the xylosyl linkage in the new saponins was determined by chemical means. Previously reported vaccaric or segetalic acid-type
bisdesmosides could not be detected in any of the extracts. Copyright © 2006 John Wiley & Sons, Ltd.
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INTRODUCTION
The plant Saponaria vaccaria L. (Caryophyllaceae)†† is
widely distributed throughout Eurasia, where it is a
native species, and North America, where it is an intro-
duced species (Frankton and Mulligan, 1987). Several
accessions of S. vaccaria have previously been investi-
gated as a potential new crop for the northern great
plains region, owing mainly to the excellent agronomic
characteristics of this species and the high content of a
unique, small-grained starch (Goering and Brelsford,
1966; Goering et al., 1966; Mazza et al., 1992;
Biliaderis et al., 1993). In addition to its attractive
agronomic characteristics, the plant also possesses
interesting medicinal properties—the seed is used in
traditional Chinese medicine (Wang-Bu-Liu-Xing) as a
galactagogue and treatment for amenorrhoea and
breast infections (Huang, 1994; Sang et al., 2003a).
Accordingly, there have been at least two reviews on
the phytochemistry of the seed, which is particularly
rich in triterpene saponins as well as containing
significant amounts of small (n = 5–9) cyclic peptides
(cyclopeptides) and C-glycosylflavonoids (Jia et al.,
2002; Sang et al., 2003b). The triterpene saponins
previously identified included a large number of both
mono- and bisdesmosides, with the latter, the predomi-
nant components, all having been characterised as
sapogenin C-3-O-disaccharide, C-28-O-sugar esters,
i.e. 3-O-β-D-Galp-(1 → 2)-β-D-GlcpA, 28-O-β-D-Xylp-(1
→ 4)-α-L-Rhap-(1 → 2)-[α-L-Araf-(1 → 3)]-β-D-4-O-
acetylFucp derivatives of gypsogenin, and quillaic, vaccaric
and segetalic acids, often having further acetyl substitu-
tion in the sugar ester side chain (e.g. structures 1–5).
Although a large amount of isolation and structure
elucidation work has been performed with this plant,
little in the way of analytical or profiling work has been
carried out. Previously, saponins from a number of
other plant species have been analysed using HPLC
methods, which, particularly when coupled to a mass
spectrometer, have proven useful in identifying and
analysing saponin containing extracts (Hostettmann
and Marston, 1995; Lee et al., 1999; Perret et al., 1999;
Sturm and Stuppner, 2000; Berhow et al., 2002).
We were interested in screening plants of this species
for specific ‘chemotypes’ which, it was felt, might be
useful as sources of medicinal and/or industrial
agents. In order to compare various accessions, a con-
venient method for identifying and profiling some of
the main components was developed. This paper
describes an HPLC method that makes use of a
benchtop single quadrupole mass spectrometer em-
ploying negative ion electrospray ionisation (ESI−) and
a photodiode array detector (PAD), for investigating
* Correspondence to: J. J. Balsevich, Plant Biotechnology Institute,
National Research Council of Canada, 110 Gymnasium Place,
Saskatoon, Saskatchewan, Canada S7N 0W9.
E-mail: john.balsevich@nrc-cnrc.gc.ca
† NRCC No. 48025.
†† Syn. Vaccaria segetalis, v. hispanica, v. pyramidata. Common name:
cow cockle or cow herb.
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and identifying bisdesmosidic saponins in Saponaria
seed. The described method has been used to profile
these compounds in extracts derived from three plant
sources: a local wild-type accession, a horticultural
variety and a commercial herbal product.
EXPERIMENTAL SECTION
General
Solid-phase extraction was carried out with Waters
Sep-Pak Vac t-C18 SPE cartridges (Milford, MA, USA).
Analytical TLC was performed with Macherey-Nagel
(Easton, PA, USA) pre-coated Alugram SIL G/UV254
(0.2 mm layer thickness). Preparative TLC was per-
formed on Sigma-Aldrich (St Louis, MO, USA) glass
plates (20 × 20 cm; 0.25 mm). Distilled de-ionised
water was used for analytical applications.
Plant material and saponin extracts
Seed of S. vaccaria ‘Scott WT’ was obtained from Eric
Johnson, Agri-Food and Agriculture Canada, Scott
Experimental Farm, Scott, Saskatchewan. Seed of S.
vaccaria cv. ‘Pink Beauty’ was obtained from CN Seeds
Ltd, Pymoor, UK. The herbal extract, Wang-Bu-Liu-
Xing, was purchased from a mail order supplier,
Botanicum Herbs (botanium.com). Quillaja saponin
(S4521), having sapogenin content of approximately
25% (<10% ash), was purchased from Sigma.
HPLC-MS-PAD analysis
A Waters Alliance 2695 chromatography system with
inline degasser, coupled to a ZQ 2000 mass detector
and a 2996 PAD, was used for analyses. Waters
MassLynx v. 4.0 software was used for data acquisition
and manipulation. The columns used were a Waters
Symmetry RP C18 (150 × 2.1 mm i.d.; 3.5 µm), a Waters
Sunfire RP C18 (150 × 2.1 mm i.d.; 3.5 µm) or a
Phenomenex (Torrance, CA, USA) Synergi MAX-RP 80A
C12 (250 × 2.0 mm i.d.; 4 µm). The flow rate with
the Waters columns was 0.2 mL/min, and with the
Phenomenex column 0.15 mL/min. Columns were
maintained at 35°C during runs. The binary solvent
systems used were with solvent A, 0.12% acetic acid in
10% acetonitrile (aq., v/v), and solvent B, 0.12% acetic
acid in 100% acetonitrile. Gradients used were: (1)
0–3 min, 75% A–25% B; 3–25 min, 75% A–25% B to
50% A– 50% B; 25–28 min, 25% A–75% B to 100% B;
28–33 min, 100% B; and (2) 0–8 min, 90% A–10% B;
8–31 min, 90% A–10% B to 50% A–50% B; 31–33 min,
50% A–50% B to 100% B; 33–48 min, 100% B. Injec-
tion volumes of 5 µL were typical.
Unless otherwise noted, the mass detector para-
meters (ESI−) were set to capillary (kV) 2.70, cone (V)
−30 to −90.0 over a masss range of 400–1900, extractor
(V) −3.50 and RF lens (V) −0.7. PAD was performed over
the range 200– 400 nm, and saponins were monitored
at 209 nm.
Extraction and fractionation
For HPLC-PAD-MS analysis. Seed (50 mg) was crushed
and extracted with 70% methanol (2 mL) by mixing and
standing at ambient temperature for 2 h. The mixture
was centrifuged (microfuge) and the supernatant
filtered through a 0.45 µm nylon filter into a sample
tube.
For isolation of wild-type saponins. Wild-type seed
(10 g) was ground and de-fatted with hexane. The de-
fatted meal was extracted with 70% methanol (60 mL)
by stirring at ambient temperature for 20 h. The meal
was separated by centrifugation and extracted a
second time with 70% methanol (25 mL) for 4 h.
The combined methanolic extract was concentrated
in vacuo to afford an amber solid (0.7 g), which was
dissolved in water and applied to a conditioned and
equilibrated 10 mL SPE cartridge and eluted
sequentially with 20–40 mL portions of water, 30–60%
methanol and 70–100% methanol. Saponins were
obtained in the 70–100% fractions, which were
combined and concentrated in vacuo to afford a white
powder (230 mg).
Saponification, isolation and comparison of
prosapogenins
S. vaccaria or Quillaja saponins (100–200 mg) were
dissolved in 1 M sodium hydroxide (5 mL) and stirred
under a nitrogen atmosphere for 3 days at ambient
temperature or heated at 80°C for 4 h. The solution
was carefully neutralised with 1 M hydrochloric acid,
acidified with a small amount of citric acid (ca. 50 mg)
and applied to a 5 mL SPE cartridge and sequentially
eluted with water and 3, 70 and 100% methanol.
The prosapogenins were obtained in the 70–100%
fractions. Prosapogenins from both samples were run
on Phenomenex and Sunfire columns using both gradi-
ents, as outlined above. In addition, 1:1, 2:1 and 3:1
mixtures of the prosapogenins were run using selected
ion monitoring at m/z 955 to establish that the
prosapogenin 13 derived from Quillaja saponins was
the same as that derived from S. vaccaria saponins.
Selected ion monitoring at m/z 823 also indicated that
both reaction mixtures also contained the same 3-O-β-
disaccharide [3-O-β-D-Galp-(1 → 2)-β-D-GlcpA quillaic
acid]. The 3-O-disaccharide was a minor component in
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the Quillaja-derived prosapogenin mixture (estimated
to account for ca. <20% of prosapogenins), but a
significant component in the S. vaccaria-derived
prosapogenin mixture (estimated to account for ca. 40–
50% of prosapogenins).
Dimethyl ester of 3-O-β-D-Xylp-(1 → 3)-[β-D-Galp-
(1 → 2)]-β-D-GlcpA quillaic acid (12)
The prosapogenin mixtures (ca. 40 mg each) from
above were dissolved in methanol (5 mL) and treated
with excess diazomethane in ether. Excess diazome-
thane was destroyed by addition of a few drops of
acetic acid and the mixture was concentrated
in vacuo. The residue was chromatographed on silica
gel (PTLC) using ethyl acetate:methanol:water (30:6:1,
twice) to afford the same pure trisaccharide dimethyl
ester, based on comparison of NMR spectra and TLC
and HPLC behaviour. Previously the trisaccharide
diacid from Quillaja saponins had been isolated and
fully characterised as such (Guo et al., 1998). The
published 1H- and 13C-NMR spectra of the diacid were
obtained in methanol-d4. The C-28 methyl ester had
also previously been identified as a natural product
in Gypsophila oldhamiana and its 1H- and 13C-NMR
spectra (pyridine-d5) reported (Liu et al., 1995). We
include here our partial 1H- and 13C-NMR data (1-D) of
the dimethyl ester obtained in pyridine-d5 on a Bruker
(Milton, ON, Canada) AMX 500 MHz instrument.
Dimethyl ester 12. 1H-NMR δ: 9.93 (1H, s, H-23), 5.55
(1H, d, 7.8, H-1 galactose), 5.50 (1H, bs, H-12), 5.29
(1H, d, 7.7, H-1 xylose), 4.89 (1H, d, 7.4, H-1
glucuronic acid), 3.74 (3H, s, OCH3), 3.68 (3H, s,
OCH3), 3.37 (1H, dd, 14.3&3.5), 2.75 (1H, t, 13.5),
2.44 (1H, dt, 12.7&4), 2.21 (1H, bd, 13.7), 1.73 (3H, s),
1.45 (3H, s), 1.09 (3H, s), 1.02 (3H, s), 0.84 (3H, s),
0.81 (3H, s); 13C-NMR δ : 210.2 (C-23), 178.0 (C-28),
170.2 (C-6 glucuronic acid), 144.9 (C-13), 122.7 (C-12),
105.3 (C-1 xylose), 104.7 (C-1 galactose), 104.2 (C-1
glucuronic acid), 86.0, 84.8, 78.9, 77.1, 76.7, 75.8,
75.6, 74.6, 74.0, 71.3, 71.1, 70.5, 67.7 (C-5 xylose),
62.1 (C-6 galactose), 55.4, 52.5, 52.1, 49.3, 49.0, 47.3,
42.2, 41.6, 40.3, 38.4, 36.5, 36.2, 33.5, 32.9, 32.8,
31.2, 27.4, 25.5, 24.9, 24.0, 20.8, 17.5, 16.0, 11.4.
RESULTS AND DISCUSSION
HPLC-PAD and MS analyses
HPLC analysis of aqueous methanolic seed extracts,
using an acidified acetonitrile–water gradient (1;
see Experimental section) and a reverse-phase column
with PAD detection, afforded the profiles shown in
Fig. 1. The extracts were prepared with minimal
processing in order to obtain as true a profile as
possible. The main bisdesmosidic saponins (Fig. 2)
could be separated from most of the other soluble
products (carbohydrates, phenolics, cyclic peptides
and monodesmosides) present in the crude seed
extract, and were readily detected at 209 nm, eluting
between 10 and 25 min in the system employed.
Polysaccharides, phenolics and cyclopepetides eluted
earlier than the saponins and could be easily distin-
guished via PAD at appropriate wavelengths and/
or the corresponding MS (data not shown). Also tend-
ing to elute earlier were the lower molecular weight
monodesmosidic saponins (molecular weights <1300),
which were relatively minor but still significant com-
ponents in the mixture.
The bisdesmosidic saponin profile of the wild-type
seed was complex, with more than 20 saponins
estimated (based on both UV, see Fig. 1, and mass
detection, see Fig. 3 and Table 1) as being present in
the mixture. From scrutiny of previously published
structures and the quasi-molecular ions exhibited
in the total ion chromatogram (TIC) (Fig. 3), it appeared
that a majority of bisdesmosides observed here had
not previously been identified (Table 1). Examination
of chromatograms (UV and mass detection) derived
from a commercial herbal product and a horticultural
variety, cv. ‘Pink Beauty’, indicated that the same
saponins observed in the wild-type seed extract
were also present in their extracts, but in substantially
different proportions (Fig. 1). Since the bisdesmosides
all contained the same chromophore (an isolated
double bond) and there did not appear to be other
significant UV-absorbing chromophores in this
region, the obtained profiles reflected the relative
molar proportions of the various components making
up the peaks. In the herbal product (Fig. 1), the main
bisdesmoside was observed to be the known com-
pound, vaccaroside E (1, ca. 13.45 min, MW 1422.6),
whereas in the wild-type and ‘Pink Beauty’ accessions,
a higher proportion of the acetylated analogue,
segetoside I (2, ca. 18.2 min, MW 1464.6) was
noted. In addition, the herbal product appeared to
have lower relative amounts of the later eluting
saponins and greater relative amounts of the earlier
eluting saponins. The assignment of peaks to the
above known saponins was based on extracting
selected mass chromatograms from the TIC, using
their molecular weights as the selection criterion. In
this manner, it was possible to confirm the presence of
known principal saponins 1–5 and identify their
elution times, as shown in Fig. 4. Furthermore, a
similar process could be used to identify the elution
times of the other saponins noted in the scan of quasi-
molecular ions exhibited in Fig. 3. A list of bisdes-
mosides identified and their retention times (from
the same run) based on their observed quasi-
molecular ions is shown in Table 1.
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Figure 1 HPLC chromatograms, 10–25 min region, of seed saponins from an S. vaccaria wild-type accession (top), horticultural
cultivar ‘Pink Beauty’ (middle), and a commercial herbal product, Wang-Bu-Liu-Xing (bottom). Chromatographic conditions: Sym-
metry C18 column, gradient 1 elution (see Experimental section), UV detection at 209 nm.
Identification of novel 3-O-trisaccharide saponins by
MS
During the course of examining the TICs, it was ob-
served that peaks due to known bisdesmosides 1–5
were associated with closely eluting or overlapping
peaks of unknown saponins that exhibited correspond-
ing quasi-molecular ions 132 mass units higher (Fig. 5).
Mass spectra generated by combining MS scans across
the appropriate chromatographic peak or portion
thereof in the TIC indicated that some key fragments
obtained from the new saponins were also 132 mass
units higher. Under the conditions employed, the main
fragmentation pathway of the bisdesmosidic saponins
was observed to be loss of sugars at the sugar ester
end (pathway a, Fig. 2), with quillaic acid saponins
such as 1–3 giving rise to a fragment ion at m/z 823
and gypsogenin saponins such as 4 and 5 affording
the corresponding fragment ion at m/z 807. Cleavage
at the 3-O glycoside end of the saponins could also be
observed at cone voltages >90 V, giving rise to ions re-
presentative of the parent aglycones, quillaic acid and
gypsogenin (i.e. m/z 485 and 469, pathways a and b,
Fig. 2). The closely eluting new saponins, in addition to
quasi-molecular ions 132 mass units higher, also ex-
hibited fragments at m/z 955 or 939 (pathway a) and
corresponding aglycone fragments at m/z 485 and 469
(pathways a and b), thus implicating them as added
sugar homologues of the known saponins 1–5, with the
added sugar being a pentose at the 3-O-glycoside end.
The fragmentation and type of ions generated in the
extracted MS were strongly dependent on the cone
voltage. At higher votages (>90 V) strong singly charged
quasi-molecular ions [M – H]−, fragments due to loss of
sugars at the ester end (pathway a, Fig. 2) and ions due
to complete loss of sugars (pathways a and b, Fig. 2)
were obtained, whereas at 30 V only doubly charged
[M – 2H]2− ions were observed. At 60 V ions due to the
loss of sugars at the ester end were observed, but not
ions due to loss of sugars at the gycosidic end (path-
way b, Fig. 2). Figure 6 shows the MS of known com-
pounds vaccaroside E, segetoside H and corresponding
new saponins 6 and 10 obtained with a cone voltage of
120 V. The relatively ‘clean’ MS observed were obtained
by using a ‘slower’ gradient HPLC system (2; see Ex-
perimental section), which allowed for better separation
of the 3-O-trisaccharide derivatives from the corre-
sponding disaccharides. The 3-O-trisaccharides were
observed to have very similar but earlier elution times
than the corresponding disaccharides, as might be
expected due to their very similar but somewhat more
polar structures (cf. Figs 4 and 5). Extending this
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Figure 2 Putative structures, deprotonated molecular [M – H]− ions, and principal fragments (generated by collision-induced dis-
sociation in the ion source) for the major bisdesmosidic saponins detected in S. vaccaria wild-type accession, using negative
electrospray ionisation (ESI−) mass spectrometry with cone voltages >90 V.
Figure 3 Quasi-molecular ions (m/z 1350–1900) generated from combined scan (ESI−) of bisdesmosidic region (10–25 min) of
total ion chromatogram derived from wild type Saponaria seed extract.
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Table 1 Bisdesmosidic saponins observed in a wild type Saponaria accession. Retention times were obtained by selected ion
extraction from TIC of appropriate quasi-molecular ion. Aglycone type (sapogenin) was determined from combined extracted mass
spectrum obtained at a cone voltage of 90 V. Slight differences in retention time on the chromatograms are due to differences in
tubing lengths leading to detectors. Disaccharide = 3-O-β-D-Galp-(1 → 2)-β-D-GlcpA; trisaccharide = 3-O-β-D-Xylp-(1 → 3)-[β-D-Galp-
(1 → 2)]-β-D-GlcpA.
[M – 3-O- Fragment Rt (min)
H]− m/z Aglycone substituents Compound ions, m/z (single run)
1394 Quillaic acid Disaccharide Unknown 823, 485 10.48
1406 Gypsogenin Disaccharide Vaccaroside G (4) 807, 469 17.81
1422 Quillaic acid Disaccharide Vaccaroside E (1) 823, 485 13.55
1436 Quillaic acid Disaccharide Unknown 823, 485 18.36
1448 Gypsogenin Disaccharide Segetoside H (5) 807, 469 22.07
1464 Quillaic acid Disaccharide Segetoside I (2) 823, 485 18.36
1478 Quillaic acid Disaccharide Unknown 823, 485 23.59
1506 Quillaic acid Disaccharide Segetoside I Ac (3) 823, 485 20.87
1526 Quillaic acid Trisaccharide Unknown 955, 485 11.27
1538 Gypsogenin Trisaccharide New saponin 9 939, 469 17.58
1554 Quillaic acid Trisaccharide New saponin 6 955, 485 13.52
1556 Quillaic acid Disaccharide Unknown 823, 485 10.60
1568 Quillaic acid Trisaccharide Unknown 955, 485 18.23
1580 Gypsogenin Trisaccharide New saponin 10 939, 469 21.69
1596 Quillaic acid Trisaccharide New saponin 7 955, 485 18.13
1598 Quillaic acid Disaccharide Unknown 823, 485 17.91
1610 Quillaic acid Trisaccharide Unknown 955, 485 23.27
1626 Quillaic acid Trisaccharidea New saponin 11 985, 485 17.51
1638 Quillaic acid Trisaccharide New saponin 8 955, 485 20.52
1640 Quillaic acid Disaccharide Unknown 823, 485 23.06
1688 Quillaic acid Trisaccharide Unknown 955, 485 10.69
1730 Quillaic acid Trisaccharide Unknown 955, 485 11.91
1730 Quillaic acid Trisaccharide Unknown 955, 485 17.76
1772 Quillaic acid Trisaccharide Unknown 955, 485 22.75
1814 Quillaic acid Trisaccharide Unknown 955, 485 23.53
a Trisaccharide = glucuronic acid, galactose, hexose (unknown).
Figure 4 Total and extracted ion HPLC-MS chromatograms for S. vaccaria wild-type seed extract (10–25 min region). Extracted
ions of m/z 1422, 1464, 1506, 1406 and 1448 (top to bottom) correspond to known bisdesmosidic saponins 1–5, respectively.
Slight difference in retention times on the chromatograms are due to differences in tubing lengths leading to detectors.
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Figure 5 Total and extracted ion HPLC-MS chromatograms for the S. vaccaria seed extract. Extracted ions of m/z 1554, 1596,
1638, 1538 and 1580 (top to bottom) correspond to putative new compounds 6–10, respectively.
approach, MS were extracted from the various selected
ion chromatograms that were obtained on the basis of
the quasi-molecular ions observed in Fig. 3. Examina-
tion of the resultant MS allowed the new bisdesmosides
to be categorised as to whether they possessed a di- or
tri-saccharide linkage at the 3-O-position, as well as to
which aglycone they were derived from. The overall
results are summarised in Table 1.
Figure 6 Combined extracted MS obtained from TIC of wild-type seed extract: (a) vaccaroside E (1); (b) xylosyl homologue 6;
(c) segetoside H (5); (d) xylosyl homologue 10. Cone voltage was 120 V.
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Figure 7 Outline of reactions used to establish identity and location of pentose unit in new Saponaria bisdesmosidic saponins.
Chemical identification of the main 3-O-
trisaccharide structure
Although the MS data supported the conclusion that
new saponins 6–10 were 3-O-trisachharide analogues
of the known 3-O-disaccharides 1–5, the identity and
nature of the linkage of the extra pentose unit was not
discernable from this data. In order to determine this,
the scheme outlined in Fig. 7 was used. Bisdesmosidic
saponins were obtained from wild-type seed extract via
processing on a Sep-Pak C18 column and were saponi-
fied with sodium hydroxide solution to yield a mixture
of prosapogenins (i.e. C-3-O-glycoside, C-28 carboxylic
acids). Analysis of the reaction by HPLC-PAD-MS (data
not shown) indicated that two main prosapogenins
([M – H]− at m/z 823 and 955) and several minor
prosapogenins ( [M–H]− at m/z 985, 939 and 807) were
obtained. The mixture contained approximately equiva-
lent amounts of the 3-O-di- and 3-O-tri-saccharide
prosapogenins (m/z 823 and 955), which were esti-
mated to represent close to 90% of the prosapogenin
mixture. This mixture was difficult to separate and
purify; however, treatment with diazomethane afforded
the more easily handled dimethyl esters. Chromato-
graphy on silica gel allowed for ready isolation of pure
3-O-β-D-Xylp-(1 → 3)-[β D-Galp-(1 → 2)]-β-D-GlcpA
quillaic acid dimethyl ester (12) identified as such by
comparison with the major product obtained from
commercial Quillaja saponin by the same process
(Fig. 7). The prosapogenin diacid (13) is the major
product obtainable from saponification of Quillaja
saponins and had previously been identified and fully
characterised (Guo et al., 1998). Dimethyl ester (12)
obtained separately from Quillaja and S. vaccaria
extracts was found to be identical by comparison of
1H- and 13C-NMR, as well by co-chromatography (TLC
and HPLC), conclusively establishing the structure of
the 3-O-trisaccharide portion of the main S. vaccaria
bisdesmosides. Although this type of 3-O-trisachharide
had not been previously reported in this species, it is a
common saponin structural type and has been ob-
served in other members of the Caryophyllaceae family
(Frechet et al., 1991; Jia et al., 2002; Larshini et al.,
2003) as well as being the main type found in commer-
cial Quillaja saponin preparations as noted above (Nord
and Kenne, 1999). The fact that the complex mixture of
S. vaccaria bisdesmosides, on saponification, yielded
two main prosapogenins meant that much of the struc-
tural variation between individual saponins in these
extracts was a consequence of differences in the sugar
ester portion.
The putative gypsogenin saponins 9 and 10 were
overall minor constituents and it was not possible at
this time to isolate the analogous dimethyl esters from
the saponified methylated reaction mixture produced
above to conclusively establish their trisaccharide
structures; however, based on the available data, it is
reasonable tentatively to assign their structures as
being analogous to the quillaic acid derivatives 6 and
7, analogous to the relationship of known gypsogenin
derivatives 4 and 5 with known quillaic acid derivatives
1 and 2.
All other new bisdesmosides observed in the seed
extracts with the exception of one, (11, MW 1626)
appeared to be quillaic acid derivatives with either a 3-
O-di- or tri-saccharide linkage where the trisaccharide
consisted of a glucuronic acid substituted with galac-
tose and xylose as noted above. The exception was an
unknown saponin with a molecular weight of 1626
whose MS contained fragments at m/z 985 and 485,
indicative of a quillaic acid bisdesmoside with a 3-O-
trisaccharide unit probably consisting of a glucuronic
acid, galactose and a hexose (rather than a xylose).
This compound, tentatively assigned as 11, was be-
lieved to be homologous to segetoside I (2) and
trisaccharide 7, being a sugar homologue of 2, having
an extra hexose unit at the 3-O-glycoside end and a
carbon homologue of 7, having a hexose rather than a
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similar areas in the wild-type extract, indicating similar
and significant amounts of both. In the ‘Pink Beauty’
cultivar there was very little 8 present, while in the
herbal extract there was very little 3 and virtually no 8
present.
Search for segetalic or vaccaric acid bisdesmosides
Previously two C-23 nortriterpene saponins,
vaccaroside F (aglycone = C-23 norquillaic acid) and
H (aglycone = C-23 norgypsogenin), had also been
reported from Saponaria vaccaria (Jia et al., 1998).
A search for these bisdesmosidic saponins was carried
out using selected ion examination of the TICs ob-
tained from the studied extracts. Vaccaroside F (MW
1410.6, segetalic acid derivative) and vaccaroside H
(MW 1394.6, vaccaric acid derivative), under the de-
scribed conditions, were expected to yield in addition to
strong quasi-molecular ions, key diagnostic fragment
ions resulting from loss of sugars (ester end) at m/z
811 and 795 as well as ions due to the parent aglycone
at m/z 473 (segetalic acid) and 457 (vaccaric acid), re-
spectively. Although a significant quasi-molecular ion
was observed at m/z 1394, the fragment ions observed
indicated that it was a quillaic acid 3-O-disaccharide
(ions at m/z 823 and 485) and not the expected
vaccaric acid derivative, vaccaroside H (expected ions
at m/z 795 and 457). Selected ion extraction at m/z
1410, 811, 795, 473 or 457 also did not produce any
significant peaks in the TIC, indicating that these
extracts contained little or none of these types of
pentose as part of the 3-O-trisaccharide unit. All
three of these compounds had similar retention times
(Table 1), consistent with a close structural relation-
ship between them.
3-O-Trisaccharide profile differences of seed
extracts
Examination of the seed extracts obtained from the dif-
ferent plant sources indicated quite a difference in the
relative amounts of the 3-O-trisaccharides 6–10. In the
herbal extract, they were observed to be relatively
minor components (estimated at 0–20% of correspond-
ing disaccharides), whereas in the wild-type seed
extract they were quite significant (estimated at ca. 40–
110% of corresponding disaccharides). They were also
significant in the ‘Pink Beauty’ extract, but less so than
in the wild-type seed extract. The variation in amounts
of these 3-O-trisaccharide saponins relative to the
corresponding 3-O-disaccharide analogues could be
noted by examining the ratio of quasi-molecular ions
generated in the combined extracted spectra of the two
homologous components (e.g. Fig. 8) or by examining
their chromatograms obtained with PAD detection at
209 nm, using a ‘slower’ gradient where neccesary in
order to obtain greater peak separation. For example,
segetoside I Ac (3) and the corresponding xylosyl homo-
logue 8 could be readily separated even in the ‘fast’
gradient (1) used to generate chromatograms shown in
Fig. 1. The peaks at ca. 20.5 and 20.8 min correspond-
ing to these two compounds (8 and 3 respectively) had
Figure 8 Quasi-molecular ions generated from combined scan of 13–14 min range in TIC of extracts derived from Saponaria wild-
type seed (top), ‘Pink Beauty’ seed (middle), and commercial herbal extract (bottom). MW 1422 = vaccaroside E (1); MW 1554 =
xylosyl homologue 6.
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saponins. The fact that these types of saponins were
not observed in any extracts derived from three very
different plant sources, which were minimally pro-
cessed, suggested the possibility that these reported
compounds may have been artefacts, produced during
the many isolation and purification steps required to
obtain purified saponins. Thus, Baeyer–Villager type
oxidation of the C-23 aldehyde group of 1 and 4 during
processing of the extracts could lead to formate esters,
hydrolysis of which would afford the corresponding
C-23 norsaponins vaccaroside F and H. There is
precedence for Baeyer–Villager oxidation of aldehydes
yielding formate esters (Corma et al., 2005) and
hydrolysis of formate esters is known to be very facile
(Lakshmi and Balasubramanian, 2003). We believe
this speculation to be quite reasonable, although
the alternative possibility, that the C-23 norsaponins
previously reported were selectively produced by
the particular plant examined, cannot be ruled out at
this time.
In conclusion, the methodology described here
should be useful for analysis of other similar saponin
or glycoside containing extracts.
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